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ABSTRACT 
The three-arm non-inferiority trials include an experimental treatment arm, an 
active comparator arm and a placebo arm.  Such a design allows evaluating the 
assay sensitivity by testing the superiority of active comparator over placebo, and is 
a preferred choice when the constancy of the treatment effect is questionable under 
the current medical setting, or when there is no consensus on the magnitude of a 
clinically relevant treatment effect. This dissertation, investigating sample size 
recalculation in active- and placebo-controlled trials at the interim, is composed of 
three chapters. The first chapter summarizes for the three-arm non-inferiority 
design, including hypotheses formulations, testing procedures and a few important 
features. We also compare statistical power between the two forms of the non-
inferiority test: fixed margin test and effect preservation test. In the second chapter, 
the commonly used group sequential designs and sample size recalculation methods 
are reviewed, and two methods (Method I and Method II) are applied to the three-
arm non-inferiority trials with normally distributed endpoint. Method I which was 
proposed in previous publications, does not require unblinding the experimental 
treatment effect. However, it has a limitation that the sample sizes of the three arms 
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must meet specific ratios in order to control Type I error. This thesis extends this 
method to a broader range of sample size allocations.  Method II is based on the 
concept of promising zone of the conditional power. It is a modified group 
sequential design and recalculate the sample size only when the interim result is 
promising. The overall type I error control, power and efficiency of the two methods 
(I vs. II) are compared under various scenarios through simulations. It is found that 
the method I provide a substantial power gain when the initial active comparator 
effect is over-estimated at the design stage. However, it cannot handle the 
uncertainties in the experimental treatment effect. In contrast, the Method II 
controls type I error at all investigated sample size allocations. It provides moderate 
power gain if the preserved effect is over-estimated. Once the interim result is 
promising the recalculated sample size can increase the final rejection probability 
considerably.  When the experimental treatment effect is under-estimated at the 
design stage, the average sample size can reduce dramatically compared to fixed 
sample design due to the high probability of rejection at the interim stage. The third 
chapter investigates how the two methods perform for the binary endpoint. The 
formula of conditional power for binary outcome is derived. The statistical 
properties including the variance estimation, the type I error control and actual 
power are investigated through simulations. 
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CHAPTER I: THREE-ARM NON-INFERIORITY TRIALS 
1.1 Introduction and Background 
In randomized clinical trials (RCT), there are two major approaches to demonstrate 
the efficacy of a novel medical therapy: to prove the superiority of the experimental 
treatment over placebo, or to prove the superiority or non-inferiority of the 
experimental treatment to an active comparator. Placebo-controlled RCTs are often 
used for indications when no known effective and safe therapy is available. When 
there is proven efficacious therapies on the market, placebo-controlled RCTs are 
often not ethically justifiable. In some cases, if patients will not be harmed by 
deferral of therapy, placebo-controlled therapy may also be permitted. There are a 
few limitations on the RCT with placebo as the single control. Although one can 
demonstrate that the treatment difference between the experimental treatment and 
placebo is significantly different from zero, it is sometimes not clear whether the 
observed magnitude of the difference is clinically significant. For example, in many 
preventive vaccine studies, the primary endpoint is the immunogenicity (the 
vaccine’s ability to stimulate an immune response) which is often characterized by the 
concentration of a certain antibody in the blood sample. Biologically the antigen in 
the vaccine product would induce antibody production whereas the placebo rarely 
has immune response. More often than not the concentration needed to provide 
effective protection is not clear. In such case showing the superiority to placebo is 
not sufficient evidence to prove the efficacy. It is often required by the regulatory 
agency that the primary evidence being the non-inferiority to an active comparator 
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or a pre-specified positive threshold. In contrast if the superiority is not shown, it is 
important to find out whether the non-significance is truly due to no efficacy or 
possibly be due to low sensitivity of the assay used to measure the efficacy. Such 
limitations can be circumvented by having an active comparator in the same trial. 
To support the marketing approval of a new therapy for an indication with existing 
therapy available, the strongest evidence is showing superiority of experimental 
treatment in efficacy compared to the active comparator. However, in many 
therapeutic areas the proven therapies are highly effective leading to great 
challenge for the new therapies to show superiority. In such case, if there is 
sufficient evidence showing that the new therapy is not materially worse than a 
standard therapy (i.e., the active comparator) and benefits patients in other aspects, 
such as better safety profile or lower cost, it is still worth considering having such 
novel therapies on market. Trials designed to show that a new treatment is ‘not 
unacceptably worse’ than the current standard therapy is called non-inferiority 
trials. Since the introduction of non-inferiority trials in the mid-1990s there has 
been controversy about the validity and interpretation on such trials, as its design is 
complicated and is founded on assumptions that are difficult to verify1,2,3. A major 
concern on the conventional non-inferiority trials is how the assay sensitivity and 
the constancy assumption2 of the active comparator can be evaluated. As a result, 
the three-arm non-inferiority design, including an experimental treatment, an active 
comparator (reference treatment) and a placebo, was brought up. The design has 
been referred as “gold standard design”4 and is recommended by regulatory agency 
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in the United States5 as well as in Europe 6. The three-arm design is preferred for the 
medical indications where the constancy assumption is questionable, or the assay 
sensitivity is critical, or when there is no consensus on the magnitude of a clinically 
relevant treatment effect7. Such situations include but not limited to:  
(1) There is doubts in the efficacy of active comparator due to relatively large 
fluctuation in the efficacy estimates observed in different trials, or because the 
active comparator is established long ago so that the historical finding may not be 
valid or accurate in the present medical setting.  
(2) The active comparator effect is “weak” and thus it might be difficult to justify a 
negligible loss of efficacy in the present medical setting. 
(3) Constancy assumption is not valid due to varying response to both active 
comparator and to placebo. For instance, depression studies usually have such 
issues.  
(4) In a placebo-controlled clinical trial, incorporating an active comparator group 
may be needed when there is difficulty defining what constitutes a clinically 
relevant difference in efficacy by looking at the difference between experimental 
treatment and placebo alone. 
(5) Superiority to placebo might be less meaningful if the standard treatment 
significantly outperforms the experimental treatment. 
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1.2 Hypothesis Formulation and Testing Procedure 
Let µT, µA and µP represent the population means of the treatment effect under the 
experimental treatment, active comparator and placebo arms, respectively. Without 
loss of generosity, it is assumed that larger value means better treatment result. The 
following four hypothesis tests could form a closed testing procedure: 
 (1) 𝐻0,𝑇𝑃
(𝑠)
: µT ≤ µP versus 𝐻1,𝑇𝑃
(𝑠)
: µT > µP    
 (2.1) 𝐻0,𝑇𝐴
(𝑛)
: µT ≤ µA - ∆ versus 𝐻1,𝑇𝐴
(𝑛)
: µT > µA - ∆ 
where ∆ is a pre-specified fixed value called margin. When ∆ is replaced with a 
proportion of mean difference between active comparator and placebo, λ(µA-µP), the 
form of  hypothesis (2.1) became  
 (2.2) 𝐻0,𝑇𝐴
(𝑛)
: 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
≤ 1 − 𝜆  versus 𝐻1,𝑇𝐴
(𝑛)
: 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
> 1 − 𝜆   
This form is often referred to as effect preservation test or fractional test and will be 
discussed in chapter 1.3. 
 (3) 𝐻0,𝐴𝑃
(𝑠)
: µA ≤ µP versus 𝐻1,𝐴𝑃
(𝑠)
: µA > µP 
If (2.1) or (2.2) is rejected, i.e., the non-inferiority is demonstrated, one may be 
interested in testing if the treatment test is superior to the active comparator. 
 (4) 𝐻0,𝑇𝐴
(𝑠)
: µT ≤ µA versus 𝐻1,𝑇𝐴
(𝑠)
: µT > µA  
There has been controversy amongst authors regarding which hypotheses ought to 
be tested and in what hierarchy4,7–10. In general, 𝐻0,𝑇𝐴
(𝑛)
 is the primary test to establish 
non-inferiority. When the non-inferiority test 𝐻0,𝑇𝐴
(𝑛)
 is formulated as a fixed margin 
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test, there is consensus that the rejection of the 𝐻0,𝑇𝑃
(𝑠)
: µT ≤ µP is considered the 
utmost important step since superiority of test of treatment over placebo is a pre-
requisite for all the rest hypotheses tests. Whether 𝐻0,𝐴𝑃
(𝑠)
 needs be rejected is the 
most controversial. Koch and Rohmel4,8 suggested that the mandatory requirement 
of assay sensitivity is ill founded, because if active comparator fails to show 
superiority to placebo and in the meanwhile experimental treatment is superior to 
placebo, it should be considered an additional strength rather than a reason to 
doubt the experimental treatment. Therefore they proposed that in most cases the 
non-inferiority trial can be termed successful as soon as it can be demonstrated that 
the experimental treatment is superior to placebo and the experimental treatment is 
non-inferior to the reference. Hauschke and Pigeot7 argued that under a few medical 
settings when the active comparator is weak or represents a traditional standard 
with doubts in efficacy, the efficacy of the experimental treatment over placebo can 
be claimed if 𝐻0,𝑇𝑃
(𝑠)
 and 𝐻0,𝑇𝐴
(𝑛)
 are rejected. But in other scenarios when the active 
comparator is a well-established treatment, the assay sensitivity should be a 
mandatory condition to demonstrate the validity of the study.  
The controversy on the testing procedures had been focused on the hypotheses with 
fixed margin non-inferiority test though. When the non-inferiority test is formulated 
as effect preservation test, the rejection of 𝐻0,𝐴𝑃
(𝑠)
 is a prerequisite to ensure that the 
denominator of 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
 is not zero. In such case,  if both 𝐻0,𝐴𝑃
(𝑠)
 and 𝐻0,𝑇𝐴
(𝑛)
 are rejected, 
we could then derive that µ𝑇 − µ𝑃 > (1 − 𝜆)(µ𝐴 − µ𝑃) > 0, i.e., it is not necessary to 
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test the 𝐻0,𝑇𝑃
(𝑠)
 in this sense. It is also shown in the appendix I that when 𝜆  is no 
greater than 0.5, the power is almost always dominated by the non-inferiority test, 
meaning there is little chance that when the non-inferiority is demonstrated the 
hypothesis test of superiority of experimental treatment over placebo fails.   
In this thesis, when the null hypothesis for the non-inferiority test is  
µ𝑇−µ𝑃
µ𝐴−µ𝑃
≤ 1 − 𝜆 , 
the testing procedure adopted will be a two-step sequential test: 𝐻0,𝐴𝑃
(𝑠)
 followed by 
𝐻0,𝑇𝐴
(𝑛)
.  
 
1.3 Type I Error Control 
With more than one tests, we are confronted with the multiplicity issues. To control 
the familywise error rate (FWER) the testing procedure must be carefully planned, 
and adjustment should be made if necessary.  As discussed in 1.2, due to a natural 
hierarchy between the null hypotheses to be tested, control of type I error in three-
arm non-inferiority studies is often achieved by following a fixed sequence 
procedure11 and by considering the logical interrelations between the null 
hypotheses under consideration.  
The fixed sequence procedure provides a straightforward but powerful approach 
for controlling overall type I error when there are K (K≥2) hypotheses. It assumes 
that the null hypotheses H01, …, H0K have a priori order so that lower index 
corresponds to higher importance.  The procedure tests hypotheses in the order of 
low index to high index, each at level α, and stops at the first non-rejected 
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hypothesis. Let I be the set of indices of all true null hypotheses { H0,i }, and k* be the 
lowest index of true null hypotheses. Given that the testing sequence is fixed, the 
H0,k* has to be rejected before rejecting any true null hypothesis, therefore Prob(At 
least one H0,i is rejected) ≤ Prob(H0,k* is rejected)=α.  
 
1.4 Power Function and Sample Size Determination 
The power function and sample size determination depend on the distribution of 
outcome, hypothesis formulation and testing procedure. For continuous outcomes, 
we assume the observations under experimental treatment, active comparator and 
placebo are mutually independent and normally distributed with mean (µT , µA, µP) 
respectively and with common variance 𝜎2. The fixed sequence test procedure is 
used to control the family-wise type I error. If the non-inferiority test takes the form 
of fixed margin test, the first step tests the superiority of experimental treatment 
over placebo; If the non-inferiority test takes the form of effect preservation test, the 
first step tests the assay sensitivity, i.e., the superiority of active comparator over 
placebo.  
 
1.4.1. Fixed Margin Test 
The fixed margin approach is largely used in the conventional two-arm non-
inferiority trials. The formulation of key hypotheses in three-arm trial as discussed 
above include the superiority test of experimental treatment over placebo and the 
non-inferiority test: 
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(1) 𝐻0,𝑇𝑃
(𝑠)
: µT ≤ µP versus 𝐻1,𝑇𝑃
(𝑠)
: µT > µP   
(2) 𝐻0,𝑇𝐴
(𝑛)
: µT ≤ µA - ∆ versus 𝐻1,𝑇𝐴
(𝑛)
: µT > µA - ∆ 
Assume 𝑛𝑇  , 𝑛𝐴 and 𝑛𝑃 subjects are the sample size  for the experimental treatment, 
active comparator and placebo arms respectively, i.e., the total sample size N= 𝑛𝑇 +
𝑛𝐴 + 𝑛𝑃; The allocation of the three treatments follow the relationship of  
𝑛𝐴
𝑛𝑇
=
𝑐𝐴,
𝑛𝑃
𝑛𝑇
= 𝑐𝑃; Let ?̅?𝑇 , ?̅?𝐴 and ?̅?𝑃 be the sample means. The test statistics can be 
expressed as follows: 
𝑇𝑇𝑃
(𝑠)
=
?̅?𝑇−?̅?𝑃
𝜎
√𝑛𝑇
√1+
1
𝑐𝑃
       (1.4.1) 
𝑇𝑇𝐴
(𝑛)
=
?̅?𝑇−?̅?𝐴+Δ
𝜎
√𝑛𝑇
√1+
1
𝑐𝐴
        (1.4.2) 
 
When 𝜎 is known, or 𝜎 is unknown but sample size is large enough, the overall 
power for the testing procedure is calculated as 
  1 − 𝛽 = 𝑃({𝑇𝑇𝑃
(𝑠) > 𝑍1−𝛼} ∩ {𝑇𝑇𝐴
(𝑛) > 𝑍1−𝛼}|𝛿𝑇𝑃, 𝛿𝑇𝐶)       (1.4.3) 
Per Bonferroni inequality, the lower bound of (1.4.3) can be found as  
1 − 𝛽 = 𝑃 ({𝑇𝑇𝑃
(𝑠) > 𝑍1−𝛼} ∩ {𝑇𝑇𝐴
(𝑛) > 𝑍1−𝛼}|𝛿𝑇𝑃, 𝛿𝑇𝐴) 
            = 1 − 𝑃 ({𝑇𝑇𝑃
(𝑠) ≤ 𝑍1−𝛼} ∪ {𝑇𝑇𝐴
(𝑛) ≤ 𝑍1−𝛼}|𝛿𝑇𝑃, 𝛿𝑇𝐴)      
            ≥ 1 − 𝑃(𝑇𝑇𝑃
(𝑠) ≤ 𝑍1−𝛼|𝛿𝑇𝑃) − 𝑃 ({𝑇𝑇𝐴
(𝑛) ≤ 𝑍1−𝛼}|𝛿𝑇𝐴) 
           = 1 − 𝛽𝑇𝑃 − 𝛽𝑇𝐴      (1.4.4) 
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 𝛽𝑇𝑃 𝑎𝑛𝑑 𝛽𝑇𝐴 are respectively the type II error for the two hypotheses, 𝑍1−𝛼 is the 
1 − 𝛼 percentile of normal distribution and is the critical value for each test. For 
example, if the power of first and second step are both powered at 80%, the lower 
bound for overall power is 60%. It is nice to have a boundary, however, as shown in 
the example, it is too conservative to be used in real clinical trials.  
By examining the vector Т= (𝑇𝑇𝑃
(𝑠)
, 𝑇𝑇𝐴
(𝑛)
)’, we find that both statistics are linear 
combination of the means of three groups. The group means all follow normal 
distributions, therefore any linear combination of 𝑇𝑇𝑃
(𝑠)
 and 𝑇𝑇𝐴
(𝑛)
 are normally 
distributed. That is to say, the vector Т= (𝑇𝑇𝑃
(𝑠)
, 𝑇𝑇𝐴
(𝑛)
)’ follows bivariate normal 
distribution. Hence, it is possible to calculate the overall power directly which will 
lead to a more efficient sample size design. Specifically, the expectation of the vector 
Т is 
E ((𝑇𝑇𝑃
(𝑠), 𝑇𝑇𝐴
(𝑛))
′
) = (
𝜇𝑇−𝜇𝑃
𝜎
√𝑛𝑇
√1+
1
𝐶𝑃
,
𝜇𝑇−𝜇𝐴+Δ
𝜎
√𝑛𝑇
√1+
1
𝐶𝐴
 ) ′  (1.4.5) 
The covariance between the two statistics is  
 Cov ((𝑇𝑇𝑃
(𝑠), 𝑇𝑇𝐴
(𝑛))
′
) 
= 𝜎−2√(
1
𝑛𝑇
+
1
𝑛𝑃
)
−1
(
1
𝑛𝑇
+
1
𝑛𝐴
)
−1
) 𝐶𝑜𝑣(?̅?𝑇 − ?̅?𝐴, ?̅?𝑇 − ?̅?𝑃) 
= 𝜎−2√
𝑛𝑇𝑛𝑃
𝑛𝑇 + 𝑛𝑃
𝑛𝑇𝑛𝐴
𝑛𝑇 + 𝑛𝐴
𝜎2
𝑛𝑇
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= √
𝑐𝐴𝑐𝑃
(1+𝑐𝑃)(1+𝑐𝐴)
       (1.4.6) 
The three arms are independent and thus the covariance between the means of any 
two arms is zero. Therefore we have T ~ Bivariate Normal(𝝁, 𝚺 ), where 
  𝝁 = (
𝜇𝑇−𝜇𝑃
𝜎
√𝑛𝑇
√1+
1
𝐶𝑃
,
𝜇𝑇−𝜇𝐴+Δ
𝜎
√𝑛𝑇
√1+
1
𝐶𝐴
 ) ′, 𝚺 = (
1 √
𝑐𝐴𝑐𝑃
(1+𝑐𝑃)(1+𝑐𝐴)
√
𝑐𝐴𝑐𝑃
(1+𝑐𝑃)(1+𝑐𝐴)
1
) 
 
The power function can then be derived as 
1 − 𝛽 = Φ𝚺(
𝜇𝑇−𝜇𝑃
𝜎
√𝑛𝑇
√1+
1
𝐶𝑃
− 𝑧1−𝛼,
𝜇𝑇−𝜇𝐴+Δ
𝜎
√𝑛𝑇
√1+
1
𝐶𝐴
− 𝑧1−𝛼)          (1.4.7) 
where Φ𝚺 is the CDF of bivariate normal distribution with mean 0 and covariance 𝚺.  
The sample size 𝑛𝑇  can then be resolved by grid searching the bivariate normal 
distribution probability function. The total sample size needed to achieve a power of 
1 − 𝛽 is 𝑁 = 𝑛𝑇(1 + 𝑐𝐴 + 𝑐𝑃).  
 
1.4.2 Effect Preservation Test 
 
The effect preservation approach is also referred to as effect retention test, or 
fractional test. Rather than assuming a fixed margin, the purpose of this approach is 
to show that the experimental treatment preserves a fraction (1 − λ) of the active 
comparator effect relative to placebo. The attractive properties of this test was 
discussed in several works12,13. First of all, such design circumvents the issue of 
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problematic specification of an absolute non-inferiority margin. Such fixed margin 
was usually estimated based on historical studies. However, there is often difficulty 
to determine the pre-specified margin due to (1) few pioneer studies on the 
experimental treatment; (2) the variability of the response from trial to trial; or (3) 
differences between the analysis populations and medical environment from 
historical samples and the current study. In addition, after non-inferiority is proved 
at a pre-specified criterion (e.g., λ =0.2), this design allows a decrease of λ in a 
continuous manner until statistical significance no longer applies. With λ ≤ 0, one 
shows that the experimental treatment is “nominally superior” to the reference 
treatment. The minimum value of λ for the achieved statistical significance at level α 
is the lower 1- α confidence bound for 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
. 
The formulation of primary hypotheses can be written as follows:  
(1) 𝐻0,𝐴𝑃
(𝑠)
: µA ≤ µP versus 𝐻1,𝐴𝑃
(𝑠)
: µA > µP   
(2) 𝐻0,𝑇𝐴
(𝑛)
: 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
≤ 1 − 𝜆  versus 𝐻1,𝑇𝐴
(𝑛)
: 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
> 1 − 𝜆  
By re-arranging null hypothesis in step 2 to µ𝑇 − µ𝑃 − (1 − 𝜆)(µ𝐴 − µ𝑃) ≤ 0, the test 
statistics can be defined as 𝑇𝑇𝐴
(𝑛) = X̅𝑇 − X̅𝑃 − (1 − 𝜆)(X̅𝐴 − X̅𝑃) = X̅𝑇 − (1 − 𝜆)X̅𝐴 −
𝜆X𝑃.  𝑇𝑇𝐴
(𝑛) is a linear combination of normal distributed variables, therefore it 
follows the normal distribution with mean µ𝑇 − (1 − 𝜆)µ𝐴 − 𝜆µ𝑃 and variance 
𝜎2
𝑛𝑇
(1 +
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
).  𝑇𝐴𝑃
(𝑠)
, 𝑇𝑇𝐴
(𝑛)
 follows bivariate normal distribution based on the 
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same logic used in 1.4.1. Under the commonly used alternative hypothesis of 𝜇𝑇 =
𝜇𝐴, the overall power function can be derived as  
1 − 𝛽 = 𝛷𝜮(
ΔAP
𝜎
√𝑛𝑇
√
1
𝑐𝐴
+
1
𝑐𝑃
− 𝑧1−𝛼,  
𝜆ΔAP
𝜎
√𝑛𝑇
√1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
− 𝑧1−𝛼)            (1.4.8) 
Where ΔAP = 𝜇𝐴 − 𝜇𝑃, 𝜮 =
[
 
 
 
 
 
 𝟏
𝜆
𝑐𝑃
−
1−𝜆
𝑐𝐴
√(
1
𝑐𝐴
+
1
𝑐𝑃
)(1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
)
𝜆
𝑐𝑃
−
1−𝜆
𝑐𝐴
√(
1
𝑐𝐴
+
1
𝑐𝑃
)(1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
)
𝟏
]
 
 
 
 
 
 
,  Φ𝚺 is the CDF 
of bivariate normal distribution with mean vector 0 and covariance matrix 𝚺.  
 
Mathematically 𝜆 can take any positive values. Whereas in real world it is almost 
impossible for a new treatment to get approval if it preserves less than half of the 
control effect. Therefore all the discussions throughout this thesis will be limited on 
𝜆 ≤ 0.5. Schwartz and Denne14 did simulations to show that to achieve the same 
nominal power only a fraction (<50%) of sample size for non-inferiority test is 
required for the test of assay sensitivity when 𝜆 ≤ 0.5 when the treatment allocation 
is at 𝑐𝐴 = 1 − 𝜆  and 𝑐𝑃 = 𝜆. Therefore in their design the sample size calculation is 
dominated by the non-inferiority test. Here we will prove this in theory and also 
extend to see if this conclusion also applies to other treatment allocations. 
The sample size needed for the non-inferiority test and for the assay sensitivity test 
in the experimental treatment arm are respectively 
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nT
NIF =
{1 +
(1 − λ)2
cA
+
λ2
cP
} σ2(z1−α + z1−β)
2
λ2ΔAP
2  
nT
AP =
{
1
cA
+
1
cP
} σ2(z1−α + z1−β)
2
ΔAP
2  
Therefore, by taking the ratio, we have  
nT
NIF
nT
AP =
1 +
(1 − λ)2
cA
+
λ2
cP
{
1
cA
+
1
cP
} λ2
 
= 1 +
1+
1
cA
−
2λ
cA
{
1
cA
+
1
cP
}λ2
       (1.4.9) 
When 𝜆 < 0.5, the ratio is always greater than 1. 
Specifically at the allocation of 𝑐𝐴 = 1 − 𝜆  and 𝑐𝑃 = 𝜆,  
nT
NIF
nT
AP =
1 + 1 − λ + λ
{
1
1 − λ +
1
λ} λ
2
=
2(1 − λ)
λ
=
2
λ
− 2 
As 0 < λ ≤ 0.5, we have 2 ≤
nT
NIF
nT
AP < ∞, i.e., the sample size needed for the assay 
sensitivity is ≤ 50% of the sample size for non-inferiority test.  
 
Table 1 Ratio of sample size required to test non-inferiority over sample size for the assay 
sensitivity test at the same nominal power 
 
Allocation 𝛌 
𝒏𝐓: 𝒏𝑨: 𝒏𝑷 0.1 0.2 0.3 0.4 0.5 
1:1:1 91 21 8.8 4.75 3 
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2:2:1 61 14 6.2 3.5 2.3 
3:3:1 46 11 4.9 2.9 2 
4:4:1 37 9 4.1 2.5 1.8 
5:5:1 31 7.7 3.6 2.25 1.7 
2:1:1 66 14.8 6 3.2 2 
4:2:1 44 10 4.3 2.4 1.7 
  
We cannot enumerate all possible treatment allocations, but Table 1 listed out the 
ratios for the most commonly seen allocations, including the balanced design 
(𝑛T: 𝑛𝐴: 𝑛𝑃 = 1: 1: 1) and partially balanced designs (𝑛T: 𝑛𝐴 = 1: 1). It is observed 
that the ratio decreases as λ increases. When λ ≥ 0.4, the sample size for the test of 
assay sensitivity is less than half of that for the test of non-inferiority test. Only at λ 
= 0.5 and at allocations where the treatment is at least four times placebo the ratios 
are lower than 2, but still close to 2.  
In addition, the power functions were plotted and compared. It is shown that the 
power for the assay sensitivity test is always dramatically higher than the power for 
the non-inferiority test. As the power goes higher the overall power function curve 
overlap with the power function curve for the non-inferiority test.   
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Figure 1 Plots of power function curves for the non-inferiority test (NI), the assay 
sensitivity test (AST) and overall power for both tests  
 
Due to this observation, the sample size for such study is dominated by the three-
arm non-inferiority test. And this conclusion will be the basis for the initial sample 
size calculation for adaptive design discussed later. 
The discussion so far has all assumed that the test statistics are normally 
distributed. However, the sample size is not always big enough to apply the Central 
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Limit Theory. Pigeot and et al.10 published their work that is applicable to more 
generalized scenarios. In their study, when 𝜎2 is unknown and replaced with sample 
variance, non-central T-test with degree freedom of n𝑇 + n𝐶 + n𝑃 − 3 was used to 
calculate the exact power and sample size for the non-inferiority test.  Under various 
parameter combinations explored, sample size per group compared to normal 
approximation always differed by one only.  
1.4.3 Comparison of Power for Fixed Margin Test and Effect Preservation Test  
It is noteworthy that fixed margin test and effect preservation test can be 
transformed to one another. By replacing Δ with 𝜆(𝜇𝐴 − 𝜇𝑃), the fixed margin test 
then takes the form of effect preservation test. Therefore there has been interest in 
comparing the power of the two tests at equivalent margin. Let’s use 1 − 𝛽𝐹 to 
denote power for the fixed margin test, and 1 − 𝛽𝐸  for effect preservation test. 
Assume 𝜇𝑇 − 𝜇𝐴, we have  
 
1 − 𝛽𝐹 = 𝛷 (
Δ
𝜎
√𝑛𝑇
√1+
1
𝐶𝐴
− 𝑧1−𝛼) = 𝛷 (
𝜆(𝜇𝐴−𝜇𝑃)
𝜎
√𝑛𝑇
√1+
1
𝐶𝐴
− 𝑧1−𝛼)              (1.4.3.1) 
 
 
1 − 𝛽𝐸 = 𝛷
(
 
 𝜆(𝜇𝐴−𝜇𝑃)
𝜎
√𝑛𝑇
√1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
− 𝑧1−𝛼
)
 
 
= 𝛷 (
𝜆(𝜇𝐴−𝜇𝑃)
𝜎
√𝑛𝑇
√1+
1
𝐶𝐴
+𝜆(
𝜆
𝑐𝐴
−
2
𝑐𝐴
+
𝜆
𝑐𝑃
)
− 𝑧1−𝛼)     (1.4.3.2)   
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By comparing (1.4.3.1) and (1.4.3.2) we can find that whether 1 − 𝛽𝐸 is larger or 
smaller than 1 − 𝛽𝐹 depends on the sign of 
𝜆
𝑐𝐴
−
2
𝑐𝐴
+
𝜆
𝑐𝑃
. Let L=
𝜆
𝑐𝐴
−
2
𝑐𝐴
+
𝜆
𝑐𝑃
. It can be 
easily derived that when 
𝑐𝐴
𝑐𝑃
=
2−𝜆
𝜆
 the power for the two forms with numerically 
equal margin are the same. When 
𝑐𝐴
𝑐𝑃
<
2−𝜆
𝜆
, L is negative, i.e., the power for the effect 
preservation test is higher; When 
𝑐𝐴
𝑐𝑃
>
2−𝜆
𝜆
 , L is positive, i.e., the power for the fixed 
margin test is higher. For 𝜆=0.1, 0.2, 0.3, 0.4 and 0.5, the effect preservation test 
wins this power contest when the ratio of active comparator to placebo is no greater 
than 19, 9, 5.6, 4, and 3.  
The plots below showed when the sign of L switches at different combination of 
𝑐𝐴, 𝑐𝑃 and 𝜆.   
 
Figure 2 L=
𝝀
𝒄𝑨
−
𝟐
𝒄𝑨
+
𝝀
𝒄𝑷
 over 𝒄𝑷 at different combinations of 𝝀 , 𝒄𝑨 
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As indicated in the equation, at fixed value of 𝜆 and 𝑐𝐴, L is a monotone decreasing 
function of 𝑐𝑃. In real world it is hard to justify any 𝜆 values greater 0.5, and 𝑐𝐴 is 
often between 0.5 and 1. In such case the biggest 𝑐𝑃 that keeps L positive occurs at 
𝑐𝐴 = 1 for all values of 𝜆.   
 
1.5 Optimal Sample Size Allocation 
It is well known that in two-arm studies equal allocation is used most frequently 
because it provides higher efficiency than unequal allocation. Whereas in the three-
arm trials, in certain circumstances unequal allocation may be preferred choice.  
(1) Given limited budget, one treatment may be much more expensive than the 
alternative, the trial can enroll more subjects if more people are allocated to the 
cheaper treatment.   
(2) There are more unknown things about the new treatment. Assigning more 
subjects to the new treatment allows for higher power to detect any unknown side-
effects. 
0.0 0.2 0.4 0.6 0.8 1.0
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(3) When placebo group is introduced to evaluate assay sensitivity, it is often 
desirable to keep the placebo group minimum for ethical reasons.  
(4) In three-arm designs, with pre-specified power, the most efficient allocation that 
results in the smallest total sample size is not equal allocation. Instead, it can be 
derived under different constraints and is referred to as optimal allocation. 
Pigeot et al.10 looked into optimal allocation for the effect preservation non-
inferiority test. As the total sample size can be calculated using the formula (based 
on the nT
NIF derived in 1.4.2) 
𝑁 =
{1 +
(1 − λ)2
cA
+
λ2
cP
} σ2(z1−α + z1−β)
2
(1 + cA + cP)
λ2ΔAP
2  
Under the restriction of cA = 1(i.e., equal sample size of treatment and active 
comparator), by taking the first and second derivative the equation above, the 
minimum of N is achieved at 𝑐𝑃 =
√2λ
√(1−λ)2+1
. For example, λ = 0.3 will lead to an 
restricted optimal allocation of 2.9:2.9:1, which means only 15% of the analysis 
population will receive placebo. Without restriction, the minimum N is achieved at 
cA = 1 − λ and 𝑐𝑃 = λ. In such case, 𝑁 = 2nT. 
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CHAPTER II: GROUP SEQUENTIAL DESIGN AND SAMPLE SIZE RECALCULATION 
2.1 Introduction and Background 
In traditional clinical trials, the sample size has to be determined in advance with 
pre-specified significance level, power and treatment effect to be detected, and data 
has to be collected before analysis can proceed. However, there may be large 
uncertainty in key factors that drive the sample size estimation. In addition, the 
conventional fixed sample design may not be efficient as the recruitment of patients 
usually takes a period of time and the data become available steadily and 
sequentially. For some rare diseases, the recruitment could take years. Sequential 
trial designs were introduced which allowed the accumulated data to be analyzed at 
a series of planned interim analyses during the course. Sequential trials can be 
adaptive or non-adaptive. Non-adaptive sequential designs are often called group 
sequential designs. The trial can be stopped at any planned interim analysis for 
excessive efficacy or futility. Adaptive designs allow more flexibility, permitting 
changes to some design features at some points during the trial. Allowing sample 
size adaptation helps mitigate the risk of under-powered or over-powered study.  
 
2.2 Group Sequential Design  
In the group sequential designs repeated significance testing will be performed. 
Repeated testing would inflate the overall type I error if the same critical values as 
in fixed sample design are used in the hypothesis testing at all stages.  Armitage, 
McPherson and Rowe are the first authors who investigated this issue 
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systematically15. They considered sequential observations of binomial, normal and 
exponential distribution forms, and concluded that when null hypothesis is true the 
probability of obtaining a significant result goes above the nominal significance level 
at repeated tests on the accumulated data. Table 2 below showed the overall type I 
error for repeated tests in sampling from a normal distribution with known 
variance. 
Table 2 Overall type I error for repeated tests 
 Number of repeated tests at 2-sided 
0.05 level 
Overall Significance Level if Null 
Hypothesis of No Treatment Difference 
is True 
1 0.05 
2 0.08 
3 0.11 
4 0.13 
5 0.14 
10 0.19 
20 0.25 
50 0.33 
  
In the group sequential setting with K groups of observations in two-arm studies, 
without loss of generosity, the responses of treatment and control groups are 
assumed to be normally distributed with means 𝜇𝑇 and 𝜇𝐶 respectively and known 
common variance; let the mean difference 𝜃 = 𝜇𝑇 − 𝜇𝐶  . Under null hypothesis = 0 , 
the test statistic at each stage is 𝑇𝑘 which follows standard normal distribution, the 
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critical value is 𝑐𝑘, the overall type I error is the probability of rejecting null 
hypothesis at least once. It follows straightforwardly that  
𝑃(∪𝑘=1
𝐾 {𝑇𝑘 > 𝑐𝑘}) = 1 − 𝑃(∩𝑘=1
𝐾 {𝑇𝑘 < 𝑐𝑘}) 
To avoid the inflation of type I error, the critical value 𝑐𝑘 must be adjusted to a value 
bigger than Φ−1(1 − 𝛼). Pocock (1977)16 followed the same method of numerical 
quadrature in the work of Armitage et al. to solve the critical value on equally 
spaced information levels. In this situation the critical value is a constant for all 
stages. However this may not be the most practical approach considering that the 
early stages had small sample size and thus is more difficult to declare statistical 
significance. Therefore, O’Brien and Fleming (1979) proposed a procedure with 
rejection criteria that goes more stringent over the stages. This procedure has 
conservative stopping boundary values at very early stages, and boundary values 
close to the fixed design at the final stage. In this situation, the boundary at stage k is 
proportional to √𝐾/𝑘. This approach is recommended by FDA in their 2010 
Guidance on Adaptive Designs. Wang and Tsiatis17, Emerson and Fleming18 and 
Pampallona and Tsiatis19 generalized the Pocock and O’Brien-Fleming methods to 
the power family, which use boundary values of (
𝑘
𝐾
)
−𝜌
𝐶, where 𝐶 is a derived 
constant. 𝜌 = 0 is the case of Pocock method and 𝜌 = 0.5 is the case of O’Brien-
Fleming method.  
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All these above methods require pre-specifying the total number of decision times 
K. The timing of interim analyses is information time rather than calendar time 
which creates challenges in scheduling in practice. Also it is possible that a trial may 
change the frequency of data review due to slower recruitment or other reasons. To 
add more flexibility, Lan and DeMets20 proposed a procedure based on an error 
spending function 𝛼∗(𝑡), where t is the information fraction at each stage, which can 
be approximated by the proportion of sample size at the interim analysis out of 
overall sample size. Under O’Brien & Fleming philosophy, 𝛼∗(𝑡) = 𝑑(1 − Φ(
𝑍𝛼
𝑑
√𝑡
)) , 
where d=2 for one-sided test with significance level 𝛼 and d=4 for two-sided test 
with significance level 𝛼. Under Pocock philosophy 𝛼∗(𝑡) = 𝛼ln [1 + (𝑒 − 1)𝑡].  
 
At each interim analysis, if the significance is claimed with the family-wise type I 
error controlled, the trial can be stopped for excessive efficacy. That will not only 
cut the cost but also benefit the patients so that they could have access to the novel 
effective treatment earlier. In contrary, if the interim result turns out to be not 
promising at all, the trial may also be terminated for futility. To quantify this 
stopping criterion, the concept of conditional power was brought about. Conditional 
power is defined as the statistical power to reject the null hypothesis conditioned on 
the data observed at the interim stage. With pre-determined critical value or the 
significance level calculated from alpha spending function, the conditional power 
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can be calculated at each interim analysis and can be used as an important 
parameter to guide the next step of a trial.  
 
2.3 Sample Size Recalculation 
Sample size recalculation is a type of adaptive design that adds additional flexibility 
to group sequential design. In the initial design stage there is often considerate 
uncertainty associated with the initially assumed treatment effect due to lack of 
knowledge or data from past studies, medical practice improvement, patient 
population difference and so on. In such cases the initial sample size calculated at 
the design stage may not provide adequate power or lead to inefficient 
overpowered studies.  To mitigate such risk, a number of methods have been 
proposed to re-calculate the sample size at interim stages. In this approach, one 
starts out with a relatively small initial sample size based on optimistic estimation of 
treatment effect and adapt the sample size if the interim analysis indicate that the 
initial assumption overestimate or underestimate the treatment effect.   
The most commonly used sample size re-calculation(SSR) methods include Cui-
Hung-Wang (CHW) method21 and conditional power method22,23,24. 
 
Cui-Hung-Wang (CHW) method21 
Cui et al developed an adaptive design that allow re-calculating the sample size at 
the interim stage by substituting the assumed treatment effect with the estimate 
from the interim data. With simulations, they showed that the family-wise type I 
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error can substantially increase if the final test is performed as in fixed design. 
Therefore they devised a modified final test statistics, which is a weighted average 
of the interim test statistic Z1 and initial final test statistic Z2. It was demonstrated 
that using the modified final test statistic the type I error probability is well 
preserved at the target level. Their approach can be generalized to any group 
sequential test based on the repeated significance test that can be asymptotically 
expressed as a Brownian motion process. The downside is that as patients evaluated 
after the interim stage received less weight at the final analysis, it violates the 
sufficiency principle. Therefore, Chen et-al.25 proposed in their work a modified 
weighted Z-statistic method. The null hypothesis can be rejected if both the 
weighted and un-weighted Z-statistic at the final stage are greater than the critical 
value. The type I error rate for this modified approach is less than the nominal α. In 
their investigation, the power loss due to the additional requirement is ignorable.  
 
Denne Method22 
In this method, the sample size recalculation is based on the idea of conditional 
power. The conditional power is defined as the probability of rejecting the 
hypothesis in the final stage conditioned on the data observed in the interim stage. 
The conditional power for two-arm two stage group sequential design can be 
calculated from the equation  
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𝐶𝑃𝜃(𝑛2,  𝑐2|𝑧1) = 1 − 𝛷 
[
 
 
 𝑐2√𝑛2 − 𝑧1√𝑛1 −
𝑛2 − 𝑛1
√2𝜎2
𝜃
√𝑛2 − 𝑛1
]
 
 
 
 
where 𝜃 is the treatment difference, 𝑛1 and 𝑛2 are respectively sample size at the 
first and second stage, 𝑧1 and 𝑐2 are respectively the critical value for the first and 
second stages.  
 
Initially at the design stage, the final critical value is set at 𝑐2̃ for a pre-specified 
significance level. The sample size at first and second stage are calculated based on 
the assumed treatment effect and variance. At the interim stage, a so called 
“targeted” sample size (𝑛𝑡) is calculated by substituting in the sample variance 
estimated from the interim data. Then the final sample size  𝑛2 and critical value 𝑐2 
to preserve overall type I error is found to meet the equation 
𝐶𝑃𝜃=0(𝑛𝑡, 𝑐2̃|𝑧1) = 𝐶𝑃𝜃=0(𝑛2, 𝑐2|𝑧1) and 
 𝐶𝑃𝜃=𝛥(𝑛2,  𝑐2|𝑧1) = desired conditional power 
This method preserves the type I error and improves unconditional power 
compared to CHW method. However, it is not widely used in practice because its 
complex statistical adjustment leads to difficulties in interpreting and presenting 
trial findings in the regulatory submissions. 
 
Promising Zone Method23,26,24 
 27 
 
Chen et al. 23 further developed the conditional power method and showed that if 
the interim results are promising, the sample size can be increased without 
adjusting the final hypothesis test critical value. In their work it was found that the 
conventional hypothesis test can be performed without inflating overall type I error 
if the conditional power is greater than 50%. This finding makes the application of 
the sample size adaptation design more promising because the final stage 
hypothesis test is non-controversial, intuitive, and more interpretable to clinicians 
and other non-statistician background reviewers. Gao et al.26 extended this finding 
to a broader range of conditional power and called that range promising zone.  They 
proved in theory that when the conditional power falls into a certain range, the final 
critical value can be adjusted to a value lower than the original planned value to 
obtain a size α test. In such case, keep the original planned critical value will 
preserve the overall type I error. They also showed how to find out the thresholds of 
this range. Mehta et al.24 made that work more accessible to practitioners by 
presenting it in the context of two-stage designs, tabulating explicit cut-off values 
for the promising zone under different adaptive rules based on conditional power, 
and using two actual case studies to demonstrate how to apply and interpret this 
method.  
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CHAPTER III SAMPLE SIZE RECALCULATION IN THREE-ARM NON-INFERIORITY 
TRIALS 
3.1 Effect Preservation Test, Normal Endpoint 
As discussed in chapter I, when the non-inferiority takes the form of effect 
preservation test, rejection of the assay sensitivity test is a mathematical pre-
requisite for rejection of the non-inferiority test. Therefore, in this discussion, the 
hypotheses testing procedure will include  
𝐻0,𝐴𝑃
(𝑠)
: µ𝐴 ≤ µ𝑃 versus 𝐻1,𝐴𝑃
(𝑠)
: µ𝐴 > µ𝑃   
𝐻0,𝑇𝐴
(𝑛)
: 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
≤ 1 − 𝜆  versus 𝐻1,𝑇𝐴
(𝑛)
: 
µ𝑇−µ𝑃
µ𝐴−µ𝑃
> 1 − 𝜆  
and fixed sequence testing will be used at each stage to preserve the stage-wise type 
I error.  
The formula of  
𝑁 = nT(1 + cA + cP) =
{1 +
(1 − λ)2
cA
+
λ2
cP
} σ2(z1−α + z1−β)
2
(1 + cA + cP)
λ2ΔAP
2  
discussed in chapter 1.4 will be used for the initial sample size calculation. In 
practice there is little interest in a new treatment that preserves less than 50% 
effect of the active comparator, therefore all the discussions below will be restricted 
at λ < 0.5. 
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3.1.1 Method 1: Two-Stage SSR Based on the Observed Treatment Effect 
of the Active Comparator Effect (?̂?𝑨𝑷
(𝟏)
) 
Schwartz and Denne14 proposed a two-stage SSR method for three-arm Non-
Inferiority Trial in such setting. In their method, at the interim stage, the sample size 
will be re-calculated through replacing the initial 𝛥𝐴𝑃 with ?̂?𝐴𝑃
(1)
 computed from the 
interim data. At the final stage, the assay sensitivity and non-inferiority tests will be 
performed sequentially at a significance level of α.   
3.1.1.1 Overall Type I Error Preservation 
At Optimal allocation 
It is proved by Schwartz and Denne14 that this procedure preserves overall type I 
error at α when the sample size allocation is at nA=k(l-λ)nT, and nP =kλnT  (k=1 is 
optimal allocation).  The proof is based on the notion that recalculating the sample 
size using an estimate of a parameter that is independent of the first-stage test 
statistic will not substantially inflate the type I error at the final stage.  
Proof: 
Let 𝑍(1) and 𝑍(2) be the test statistics at the interim and final stage respectively, 
𝑍(2−1) be the test statistic constructed with only the data at the second stage. 
𝑍(1) =
?̅?𝑇
(1)
− (1 − 𝜆)?̅?𝐴
(1)
− 𝜆?̅?𝑃
(1)
𝜎
√𝑛𝑇
(1)
√1 +
(1 − 𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
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𝑍(2) =
?̅?𝑇
(2)
− (1 − 𝜆)?̅?𝐴
(2)
− 𝜆?̅?𝑃
(2)
𝜎
√𝑛𝑇
(2)
√1 +
(1 − 𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
 
𝑍(2−1) =
?̅?𝑇
(2−1)
− (1 − 𝜆)?̅?𝐴
(2)
− 𝜆?̅?𝑃
(2)
𝜎
√𝑛𝑇
(2)
√1 +
(1 − 𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
 
 
 𝑍(2) can be written as a weighted average of 𝑍(1) and 𝑍(2−1) 
𝑍(2) = √
𝑛𝑇
(1) 
𝑛𝑇
(2) 
𝑍(1) + √
𝑛𝑇
(2−1) 
𝑛𝑇
(2) 
𝑍(2−1)     (3.1.1) 
under 𝐻0, 𝑍
(1), 𝑍(2) and 𝑍(2−1) all follows standard normal distribution. 𝑍(2−1) is 
independent of Δ̂𝐴𝑃
(1)
 as it is solely formed from the data at the second stage,  
 
 𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝑇𝑦𝑝𝑒 𝐼 𝑒𝑟𝑟𝑜𝑟 = 𝑃(𝑍(2) > 𝑧1−𝛼|Δ̂𝐴𝑃
(1), 𝐻0) 
, and   
𝑍(1) =
?̅?𝑇
(1)
−(1−𝜆)?̅?𝐴
(1)
−𝜆?̅?𝑃
(1)
𝜎
√𝑛
𝑇
(1)
√1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
~𝑁(0, 1) under 𝐻0 
Δ̂𝐴𝑃
(1)
= ?̅?𝐴
(1)
− ?̅?𝑃
(1)
~𝑁(Δ𝐴𝑃,
𝜎2
𝑛𝑇
(1) ( 
1
𝑐𝐴
+
1
𝑐𝑃
)) 
Any linear combination of 𝑍(1) and Δ̂𝐴𝑃
(1)
 are linear combination of ?̅?𝐴
(1)
, ?̅?𝑇
(1)
 and ?̅?𝑃
(1)
, 
which follows normal distribution. Therefore  𝑍(1) and Δ̂𝐴𝑃
(1)
 are jointly bivariate 
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normal. 
Let C= > 0 
𝐶𝑜𝑣(𝑍(1), Δ̂𝐴𝑃
(1)) = (
𝜎
√𝑛𝑇
(1)
√1 +
(1 − 𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
)−1𝐶𝑜𝑣(?̅?𝑇
(1) − (1 − 𝜆)?̅?𝐴
(1) − 𝜆?̅?𝑃
(1), ?̅?𝐴
(1) − ?̅?𝑃
(1)) 
=
[−
(1−𝜆)
𝑐𝐴
+
𝜆
𝑐𝑃
]
√1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
       (3.1.2) 
At optimal allocation, 𝑐𝐴 = 1 − 𝜆, 𝑐𝑃 = 𝜆, 𝐶𝑜𝑣(𝑍
(1), Δ̂𝐴𝑃
(1)) = 0 according to (3.1.2) 
therefore 𝑍(2) is independent with Δ̂𝐴𝑃
(1)
  as well. 𝑃(𝑍(2) > 𝑧1−𝛼|Δ̂𝐴𝑃
(1), 𝐻0) =
𝑃(𝑍(2) > 𝑧1−α| 𝐻0) = 𝛼 
 
At other allocations  
In this thesis, it is further demonstrated that such two-stage SSR will not have type I 
error inflation when the allocation met the condition:  
𝑐𝑃
𝑐𝐴
≥
𝜆
(1−𝜆)
 . 
Proof: 
Under this condition, 
 𝐶𝑜𝑣(𝑍(2), Δ̂𝐴𝑃
(1)) = 𝐶𝑜𝑣 (√
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
𝑍(1), Δ̂𝐴𝑃
(1)) =
√
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
[−
(1−𝜆)
𝑐𝐴
+
𝜆
𝑐𝑃
]
√1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
        (3.1.3) 
 32 
 
At the condition of 
𝑐𝑃
𝑐𝐴
≥
𝜆
(1−𝜆)
 , 𝐶𝑜𝑣(𝑍(2), Δ̂𝐴𝑃
(1)) is negative. Let 𝜌 =
𝐶𝑜𝑣(𝑍(2),Δ̂𝐴𝑃
(1)
)
√𝑉𝑎𝑟(𝑍(2))∗𝑉𝑎𝑟(Δ̂𝐴𝑃
(1)
)
≤ 0. Given that the hypothesis for assay sensitivity must be 
rejected before non-inferiority test can be performed, we know Δ̂𝐴𝑃
(1)
> 𝑧1−𝛼√
2𝜎2
𝑛𝑇
(1) > 0.  
As the 𝑍(2) and Δ̂𝐴𝑃
(1)
 jointly follow bivariate normal distribution, we can derive the 
conditional distribution 
  𝑍(2)|Δ̂𝐴𝑃
(1)
, 𝐻0~𝑁( 𝜌
𝜎
𝑍
(2)
𝜎
Δ̂𝐴𝑃
(1)
Δ̂𝐴𝑃
(1)
, 1 − 𝜌2)    (3.1.4) 
We then can derive the upper limit of the rejection probability at the final stage 
conditioned on Δ̂𝐴𝑃
(1)
 and 𝐻0 
𝑃(𝑍(2) > 𝑧1−𝛼|Δ̂𝐴𝑃
(1)
,𝐻0) 
= 𝑃
(
 
 
𝑍(2) −  𝜌
𝜎𝑍(2)
𝜎
Δ̂𝐴𝑃
(1)
Δ̂𝐴𝑃
(1)
√  1 − 𝜌2
>
𝑧1−𝛼 −  𝜌
𝜎𝑍(2)
𝜎
Δ̂𝐴𝑃
(1)
Δ̂𝐴𝑃
(1)
√  1 − 𝜌2
|| Δ̂𝐴𝑃
(1)
,𝐻0
)
 
 
 
= 1 − Φ(
𝑧1−𝛼 −  𝜌
𝜎𝑍(2)
𝜎
Δ̂𝐴𝑃
(1)
Δ̂𝐴𝑃
(1)
√  1 − 𝜌2
) 
Under the condition of 𝜌 ≤ 0, Δ̂𝐴𝑃
(1)
> 0, we have 𝑧1−𝛼 −  𝜌
𝜎
𝑍
(2)
𝜎
Δ̂𝐴𝑃
(1)
Δ̂𝐴𝑃
(1)
≥ 𝑧1−𝛼 
Also  √  1 − 𝜌2 ≤ 1, therefore  
𝑧1−𝛼− 𝜌
𝜎
𝑍
(2)
𝜎
Δ̂𝐴𝑃
(1)
Δ̂𝐴𝑃
(1)
√  1−𝜌2
> 𝑧1−𝛼,  
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1 − Φ
(
 
 
𝑧1−𝛼 −  𝜌
𝜎𝑍(2)
𝜎
Δ̂𝐴𝑃
(1)
Δ̂𝐴𝑃
(1)
√  1 − 𝜌2
)
 
 
≤ 1 − Φ(𝑧1−𝛼) = 𝛼 
 
Simulation Results  
Simulations also demonstrated that when the allocations yield non-positive 
correlation between 𝑍(1) 𝑎𝑛𝑑  Δ̂𝐴𝑃
(1)
 , increasing sample size would not inflate the 
overall type I error. In contrary, the inflation can be observed when 
𝑐𝑃
𝑐𝐴
<
𝜆
(1−𝜆)
 . The 
false rejection rate in simulations with 100,000 trials under different 𝜆s and 
allocations are shown in table 3 below.  
Table 3 False rejection rate in simulations under different allocations. 
  𝒏𝑻: 𝒏𝑨: 𝒏𝑷 
𝜆 Optimal 
1:(1-𝜆): 𝜆 
1:1:1 2:1:1 2:2:1 4:4:1 
0.1 2.47% 2.39% 2.35% 2.40% 2.46% 
0.2 2.49% 2.29% 2.30% 2.39% 2.51% 
0.3 2.52% 2.34% 2.36% 2.43% 2.67% 
0.4 2.46% 2.43% 2.32% 2.59% 2.87% 
0.5 2.54% 2.50% 2.54% 2.64% 3.04% 
Note: Simulations performed at 𝜆 = 0.3; ΔAP,Assumed = 0.6, nominal 𝛼=2.5%, number of 
simulations=100,000 
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3.1.1.2 Power and Efficiency 
Schwartz and Denne14 showed in simulation that at the optimal allocation, when the 
𝛥𝐴𝑃 is over-estimated at the initial stage, leading to inadequate power, this SSR 
method can increase the actual power close to the desired value. For instance, when 
the true 𝛥𝐴𝑃 was only 1/√2 times the assumed value at the design stage, the sample 
size given by fixed design provides only 57% power. In contrast, by recalculating the 
sample size at the interim stage while half of the initially planned subjects are 
enrolled, the power goes up to 75-79%, depending on the value of λ.  
The efficiency of a study is often characterized by the average sample size. It was 
shown by simulations that, compared the average sample size for fixed study with 
the same power, this two-stage SSR method needs 2- 40% more subjects. The 
smaller value of λ, the more efficient this method is.  
  
3.1.2 Method 2: SSR When the Conditional Power Falls Into Promising 
Zone 
The two-stage SSR method based on Δ̂𝐴𝑃
(1)
 works well where there is large 
uncertainty of the assay sensitivity. In Schwartz and Denne’s work, the performance 
of the methods were evaluated under the assumption that experimental treatment 
effect is the same as the active comparator. That is not always true in non-inferiority 
study. When there is also great uncertainty in estimating the experimental 
treatment effect, which is common in clinical studies, there is a need for an SSR 
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method that allows for adjusting the sample size based on interim results of the 
experimental treatment arm.  
A conditional power based SSR method was then developed for three-arm non-
inferiority trials in this dissertation. It borrows the idea of promising zone to 
simplify the testing procedure and for easier interpretation.  
This SSR design requires testing the hypothesis at the interim stage, therefore the 
group sequential design boundaries, such as Pocock boundary, O’Brien-Fleming 
boundary and etc. will be used to calculate the initial sample size. At the interim 
stage, the hypothesis will be tested against pre-specified critical value at the first 
stage. If both rejected, the study success may be claimed for excessive efficacy. 
Otherwise, the conditional power for the non-inferiority test is calculated. If it is 
within the promising zone, the sample size will be recalculated to achieve a desired 
conditional power, often set as the same as the initial nominal power. Otherwise the 
study will go on without sample size recalculation. One could also pre-specify a 
lower bound for the conditional power to allow the study stop for futility. At the 
final stage, the hypotheses can be performed without critical value adjustment. The 
flow chart below showed the whole procedure.   
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Figure 2 Flow chart of method 2: two-stage SSR design based on conditional 
power  
 
  
Calculate initial sample size 
using two-stage GSD boundary 
 
At the interim stage, perform 
hypothesis tests and calculate CP 
 
Stop for  
excessive efficacy 
CP in 
Promising 
Zone 
 
CP in  
Favorable  Zone 
 
Recalculate 
SS to reach 
desired CP 
 
Continue 
without SSR 
 
Perform the hypothesis tests at the final stage 
without adjusting final rejection criteria 
value 
CP in 
Unfavorable 
Zone 
 
Stop for 
futility 
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3.1.2.1 Conditional Power for Effect Preservation Non-Inferiority Test 
A key elements for this design is the conditional power calculation, which is used to 
guide the directions after interim analysis,  and is the basis for sample size re-
calculation. The analytic formula of conditional power for the non-inferiority test 
can be obtained as  
𝐶𝑃𝑁𝐼𝐹 = 1 − 𝛷{
𝑐2√𝑛𝑇
(2)
−𝑧1√𝑛𝑇
(1)
√𝑛𝑇
(2)
−𝑛𝑇
(1)
−
𝜃
𝜎√
1
𝑛
𝑇
(2)
−𝑛
𝑇
(1){1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
}
}    (3.1.5) 
Where 𝜃 = µ𝑇 − (1 − 𝜆)µ𝐴 − 𝜆µ𝑃, which equals 𝜆Δ𝐴𝑃  under alternative hypothesis; 
𝑛𝑇
(1) is the number of subjects in the experimental treatment group in stage 1 
(interim stage), and , 𝑛𝑇
(2)
 is the total number subjects from stage 1 and 2 combined; 𝑐2 is 
the critical value at the final stage; 𝑧1is the calculated value of non-inferiority test 
statistic at the interim stage. The derivation of the analytic form of the conditional 
power is shown as follows: 
For simplicity, let M=1 +
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
 
The test statistic at stage 1 is 𝑧1 =
?̅?𝑇
(1)
−(1−𝜆)?̅?𝐴
(1)
−𝜆?̅?𝑃
(1)
𝜎√
𝑀
𝑛
𝑇
(1)
 
 
By definition conditional power is the probability of rejection at the final stage 
conditioned on the interim data 𝑧1, 
 𝐶𝑃 = 𝑃
(
 
 ?̅?𝑇−(1−𝜆)?̅?𝐴−𝜆?̅?𝑃
𝜎√
𝑀
𝑛𝑇
(2)
 
> 𝑐2|𝑍1 = 𝑧1
)
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=  𝑃 (
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
(?̅?𝑇
(1)
− (1 − 𝜆)?̅?𝐴
(1)
− 𝜆?̅?𝑃
(1)
) + (1 −
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
) (?̅?𝑇
(2−1) − (1 − 𝜆)?̅?𝐴
(2−1) − 𝜆?̅?𝑃
(2−1)) > 𝑐2𝜎√
𝑀
𝑛𝑇
(2)
 
| 𝑍1 = 𝑧1) 
       =  𝑃 (
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
𝑧1𝜎√
𝑀
𝑛𝑇
(1)
 
+
𝑛𝑇
(2)
− 𝑛𝑇
(1)
 
𝑛𝑇
(2) (?̅?𝑇
(2−1) − (1 − 𝜆)?̅?𝐴
(2−1) − 𝜆?̅?𝑃
(2−1)) > 𝑐2𝜎√
𝑀
𝑛𝑇
(2)
 
| 𝑍1 = 𝑧1) 
       =  𝑃 (?̅?𝑇
(2−1) − (1 − 𝜆)?̅?𝐴
(2−1) − 𝜆?̅?𝑃
(2−1) >
𝑐2𝜎√𝑛𝑇
(2)
 𝑀−𝑧1𝜎√𝑛𝑇
(1)
𝑀
𝑛𝑇
(2)
−𝑛𝑇
(1) )   (3.1.6) 
 
Let 𝜃=µ𝑇-(1 − λ)µ𝐴 − λµ𝑃, 𝐸(?̅?𝑇
(2−1) − (1 − 𝜆)?̅?𝐴
(2−1) − 𝜆?̅?𝑃
(2−1)) = 𝜃 
𝑆𝐷(?̅?𝑇
(2−1) − (1 − 𝜆)?̅?𝐴
(2−1) − 𝜆?̅?𝑃
(2−1)) =  𝜎√
𝑀
𝑛𝑇
(2)
− 𝑛𝑇
(1)
 
 
Let T=
?̅?𝑇
(2−1)
−(1−𝜆)?̅?𝐴
(2−1)
−𝜆?̅?𝑃
(2−1)
−𝜃
𝜎√
𝑀
𝑛
𝑇
(2)
−𝑛
𝑇
(1)
  , we know  𝑇~𝑁(0, 1) 
Therefore (3.1.6) becomes  
𝑃
(
 
 
 
𝑇 >
𝑐2√𝑛𝑇
(2)
 − 𝑧1√𝑛𝑇
(1)
√𝑛𝑇
(2)
− 𝑛𝑇
(1)
−
𝜃
 𝜎√
𝑀
𝑛𝑇
(2)
− 𝑛𝑇
(1)
)
 
 
 
 
=  1 − Φ
(
 
 
 𝑐2√𝑛𝑇
(2)
 − 𝑧1√𝑛𝑇
(1)
√𝑛𝑇
(2)
− 𝑛𝑇
(1)
−
𝜃
 𝜎√
𝑀
𝑛𝑇
(2)
− 𝑛𝑇
(1)
)
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3.1.2.2 Promising Zone Determination 
Similar to two-arm two-stage studies discussed in section 2.3, it is found that there 
exists a promising zone for the conditional power for the three-arm effect 
preservation test, within which one can increase the sample size without worrying 
about type I error inflation.  
The conditional power formula (3.1.5) is a function of 𝑧1, and thus for any observed 
value of 𝑧1, the conditional power for the interim data can be calculated. If it is lower 
than the nominal power, we can then equate this formula to the nominal power (or 
any desired value) to solve for a recalculated sample size ?̃?𝑇
(2)
.  We could also find an 
adjusted ?̃?2 in pair with ?̃?𝑇
(2)
 so that the conditional error function of 
𝐶𝑃𝜃=0(?̃?2, 𝑐2̃|𝑧1) = 𝐶𝑃𝜃=0(𝑛2, 𝑐2|𝑧1).  Next, by plotting the adjusted critical value ?̃?2 
versus conditional power calculated at 𝑛2, we could find that within a certain range 
of conditional power, the adjusted ?̃?2 is lower than the initial 𝑐2. It turned out that 
the promising zone boundaries depend on the nominal power, the timing of the 
interim analysis (𝑛1/𝑛2) and the cap for the recalculated sample size (nmax). The 
same findings were reported in the work by Mehta and Pocock24 for two-arm two-
stage studies. 
In a hypothetical two-stage study design powered at 80%, with the interim stage 
being performed at 50% of the initial sample size, and the maximum recalculated 
sample size being four times the initial sample size, the promising zone ranges 
approximately from 31% to 80% (Figure 3).   
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Figure 3 Plot of adjusted final stage rejection criterion versus conditional power for 
the three-arm non-inferiority test 
 
Table 4 summarizes the lower bound of promising zone at different combinations of 
analysis timing, nmax while the nominal power is 80%. The lower bound decreases 
with increased nmax and later interim analysis.  
Table 4. The threshold of promising zones for the three-arm non-inferiority test in 
the two-stage SSR designs 
nmax (folds of original n) Fraction of sample size at 
interim look (𝒏(𝟏)/𝒏(𝟐)) 
Lower bound of promising 
zone  
2 0.5 36% 
2 0.75 33% 
4 0.5 31% 
4 0.75 30% 
∞ 0.5 31% 
∞ 0.75 30% 
Note: The lower bounds were calculated for nominal initial power of 80%. 
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3.1.2.3 Type I Error Control 
At each stage, we will first perform the assay sensitivity test and will not test the 
non-inferiority unless we reject the null hypothesis, the type I error is controlled 
stage-wise. We also showed that for the effect preservation test, the type I error is 
preserved if the sample size increase happens only when the interim result is 
promising. This way the entire procedure preserves the family-wise type I error.  
Simulations were run to look at the probability of null hypotheses rejection in the 
final stage when the parameters meet null hypotheses condition. Given the nominal 
type-I error of 2.5% we consider several combinations of 𝜆 and allocations. For each 
scenario simulations with 100,000 replicates were performed. The simulated type-I 
error and power are the proportion of the simulations that cross the boundaries at 
the final stage. Table 5 below shows that the overall type I error was well preserved 
at all the investigated scenarios.  
 
Table 5 Simulation results on the type-I error rate (%) for the proposed SSR design 
based on the conditional power 
 𝜆 
Allocations 0.1 0.2 0.3 0.4 0.5 
1:1:1 2.38 2.47 2.47 2.41 2.39 
1:(1-λ): λ 2.53 2.39 2.47 2.40 2.39 
2:1:1 2.30 2.40 2.41 2.48 2.40 
2:2:1 2.41 2.51 2.48 2.41 2.41 
4:4:1 2.39 2.42 2.39 2.25 2.22 
Note: Simulations performed conditioned on 𝛥𝑇𝑃 = (1 − 𝜆)𝛥𝐴𝑃; nominal 𝛼=2.5%, 1-β=80%, number of 
simulations=100,000. 
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3.1.2.4 Operational Characteristics by Monte-Carlo Simulations 
In this section, the actual power and average sample size are investigated via Monte-
Carlo simulations. First of all, we look into the power property and efficiency of 
method 2. Then we compare the operational characteristics of this testing methods 
to method 1 described in chapter 3.1.1.  
In many cases the placebo was introduced into such studies because the assay 
sensitivity is not constant and hard to find a good estimate. Therefore, we first 
looked at how this SSR design adapt to such uncertainties by looking into the 
rejection probabilities at each stage at the scenarios when the assay sensitivity is 
close to true value, overestimated or underestimated. The table 6 used a few 
examples to show how the proposed SSR design with interim look at 50% 
information fraction work using simulations. Assuming 𝜇𝑇 = 𝜇𝐴, 𝜆 = 0.3, with an 
overall type I error rate of 0.025 and a nominal power of 80%, when the active 
comparator assumption at the trial design stage is close to true, the expected 
probability of claiming study success is 84%. There is 16% chance of rejecting null 
hypothesis at the interim stage. The probability for the conditional power falling 
into promising zone is 23%, in which case the sample size will be recalculated. The 
expected sample size is 6% higher than the sample size needed for a fix sample 
design. When the active comparator effect was underestimated by 10%, the chance 
of rejection at the interim stage increase and the chance of conditional power falling 
into promising and favorable zone is higher. On the contrary, if the assay sensitivity 
was overestimated by a factor of √2, in which case the initial sample size is only half 
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of the needed sample size, the actual power without sample size recalculation was 
51% only. The method 2 SSR increase the actual power by 6% which is moderate 
compared to a substantial increase of more than 20% in method 1. The reason for 
the moderate increase is that the method 2 increase the sample size only when the 
interim result is promising. There is a relatively high chance that the conditional 
power goes unfavorable for which there would not be interest in investing more. 
However if the interim result happen to be in the promising zone there is a 
considerable power gain to 77% after sample size recalculation. 
Table 6 Simulation results on the operational characteristics for the proposed SSR 
design (method 2) with uncertainties in the assay sensitivity 
 Actual 
Power1 
(%) 
Probability of 
null Rejection 
at the interim 
(%) 
Average sample 
size of SSR/fixed 
sample size  
Conditional 
Power Zone Probability 
falls into 
each CP 
zone (%) 
Probability 
of null 
Rejection 
in the zone 
(%) 
ΔAP,True = ΔAP,Assumed 84 (80) 16 1.06 Unfavorable 20 43 
Promising 23 93 
Favorable 57 95 
ΔAP,True = 1.1ΔAP,Assumed 90 (87) 22 1.22 Unfavorable 15 51 
Promising 21 95 
Favorable 64 97 
ΔAP,True = ΔAP,Assumed/√2 57 (51) 6 1.15 Unfavorable 40 20 
Promising 26 77 
Favorable 34 84 
1. The numbers are actual power of the SSR design*100 (actual power without SSR).  
Note: The numbers in parenthesis are the actual power without sample size recalculation;  nominal 𝛼=2.5%,  
allocation is 1:1:1, 𝜆 = 0.3, number of simulations=100,000. 
 
In therapeutic areas with moderate to big response variations, besides the 
uncertainties of active comparator effect, it is not surprising that the experimental 
treatment preserves slightly less or more than 100% of active comparator effect. 
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However, in the previous work on the three-arm non-inferiority trials, the sample 
size calculation was always being determined assuming equivalent effect between 
treatment and active comparator, in such case the actual power will also deviate 
from the nominal power. Here we are interested in seeing how this method 2 
perform when the true experimental treatment effect differs from the active 
comparator effect.  
In table 7, the actual power was computed for each scenario by simulations. The 
actual power for the fixed sample design was presented in the parenthesis for 
comparison. In general, when the preserved effect is less than 100% but is over-
estimated at the design stage, the initial sample size does not adequately power the 
study, the method 2 SSR increases actual study rejection probability by 4% to 6%. 
This magnitude agrees with the observation by Mehta etc18 when they compared the 
group sequential design against the design with SSR at promising interim results for 
two-arm studies. When the experimental treatment is actually superior than the 
active comparator, the study using the initial sample size will have excessive power. 
In such case for the method 2 SSR design, in the interim stage there is a good chance 
of rejecting nulls and claim study success, and also a relatively high probability that 
the conditional power falls into favorable zone.  Table 8 showed average sample size 
(ASN) and the chance of rejecting the null hypotheses in the interim stage.  When 
the assumptions are close to the true values, there is around 7% increase in the 
averaged sample size associated with 4% increase of rejection probability compared 
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to the nominal power.  When treatment effect is underestimated, the ASN can be 
smaller than the sample size for fixed design due to good chance (35% - 49%) to 
reject the null hypothesis at the interim stage. In all investigated scenarios, the 
optimal allocation is still more efficient than balanced allocation although with a 
slightly (~1%) lower chance of interim stage rejection. The sample size allocations 
investigated are the balanced allocation (1:1:1) and optimal allocation (1:(1- λ): λ).  
As shown in table 7 their impact on the actual power is negligible. The optimal 
allocation requires fewer total sample size than balanced allocation in the SSR 
design as well.   
Table 7 Simulation results on the power (%) for method 2 at different combinations 
of 𝚫𝐓𝐏,𝐓𝐫𝐮𝐞, 𝚫𝐀𝐏,𝐓𝐫𝐮𝐞, and 𝚫𝐀𝐏,𝐀𝐬𝐬𝐮𝐦𝐞𝐝 
 
  ΔAP,True = ΔAP,Assumed ΔAP,True = 1.1ΔAP,Assumed ΔAP,True = ΔAP,Assumed/√2 
ΔTP,True
ΔAP,True
 
Allocations 𝜆 𝜆 𝜆 
0.2 0.4 0.5 0.2 0.4 0.5 0.2 0.4 0.5 
1 1:1:1 84 (80) 84 (80) 84 (80) 90 (87) 90 (87) 90 (87) 57 (51) 56 (51) 55 (51) 
 1:(1- λ): λ 84 (80) 84 (80) 84 (80) 90 (87) 90 (87) 90 (87) 57 (51) 56 (51) 55 (51) 
0.95 1:1:1 62 (56) 75 (70) 78 (73) 70 (64) 82 (77) 84 (80)  36 (32) 47 (41) 48 (44) 
 1:(1- λ): λ 62 (56) 75 (69) 77 (73) 70 (64) 82 (78) 84 (80)  37 (32) 46 (41) 48 (44) 
1.1 1:1:1 89 (86) 96 (94) 94 (93) >99 (98) 98 (97) 97 (96) 88 (84)  80 (75) 69 (67) 
 1:(1- λ): λ 89 (86) 96 (94) 94 (93) >99 (98) 98 (97) 97 (96) 88 (84)  79 (75) 69 (67) 
Note: The numbers in parenthesis are the actual power without sample size recalculation; nominal 𝛼=2.5%, 
number of simulations=100,000. 
 
Table 8 Simulation results on the average sample size and the interim stage rejection 
probability for method 2  
 
ΔTP,True
ΔAP,True
 
Allocations Sample size for 
fixed design 
ΔAP,True
= ΔAP,Assumed 
ΔAP,True = 1.1ΔAP,Assumed ΔAP,True
= ΔAP,Assumed/√2 
1 1:1:1 1149 1229 (16%) 1187 (22%) 1354 (5%) 
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 1:(1- λ): λ 970 1048 (15%) 1005 (21%) 1148 (3%) 
0.95 1:1:1 1149 1312 (10%) 1278 (13%) 1359 (3%) 
 1:(1- λ): λ 970 1112 (9%) 1082 (12%) 1148 (2%) 
1.1 1:1:1 1149 1032 (38%) 940 (49%) 1288 (11%) 
 1:(1- λ): λ 970 886 (35%) 802 (46%) 1100 (7%) 
Note: λ=0.3, ΔAP,Assumed = 0.6, nominal 𝛼=2.5%, number of simulations=100,000. 
 
3.1.3 Comparison Between Method 1 and Method 2 
In this thesis, first we extended the application scope of the established method 1 by 
proving that such sample size recalculation will not inflate type I error when the 
allocation met the condition:  
𝑐𝑃
𝑐𝐴
≥
𝜆
(1−𝜆)
  . When 𝜆 is no bigger than 0.5, the balanced 
allocation always meets this condition. This proof adds a great value to this SSR 
design as balanced allocation is used mostly frequently in real world.   
Furthermore, we compare the operational characteristics of the proposed method 2, 
conditional power based SSR with the method 1. The table 9 listed out which 
method preserves the type I error within the prespecified 2.5% significance level 
based on the simulation results at different combinations of λ and sample size 
allocations. There is no inflation in the type I error for both SSR methods at the 
optimal allocation (1:(1- λ): λ), the fully balanced allocation (1:1:1) and at 2:1:1 
allocation for all λ investigated. Inflations are observed for Method 1 when the 
placebo to active comparator sample size ratio is less than the cutoff value. 
Table 9 Comparison of method 1 and method 2 at overall type I error control  
  
 nT:nA:nP 
  λ 1:(1- λ): λ 1:1:1 2:1:1 2:2:1 4:4:1 
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0.1 Both Both Both Both Both 
0.2 Both Both Both Both Both 
0.3 Both Both Both Both Method 2 
0.4 Both Both Both Method 2 Method 2 
0.5 Both Both Both Method 2 Method 2 
 
Note: BOTH = The overall type I error was both controlled at 2.5% level; Method 2= The overall type I error was 
controlled using method 2 and inflation was observed using method 1. 
Simulations performed conditioned on ΔTP=(1-λ)ΔAP; nominal α=2.5%, number of simulations=100,000.  
 
 
The power comparisons were then performed at balanced allocations for various 
combinations of the over-estimated or under-estimated parameters. The simulation 
results are shown in Table 10. It is found that whenever the assay sensitivity ΔAP is 
over-estimated, sample size recalculation based on the observed ?̂?𝐴𝑃
(1)
 can make up 
the majority power loss due to the inaccurate estimation of ΔAP. This agrees with the 
conclusion from the work by Schwartz and Denne8 where the method 1 is originally 
proposed. In contrast, the method 2 increase the power moderately, ranges from 4 
to 7% for over-estimated parameters. However when the sample size increase 
happens due to promising interim result for method 2 the power gain is substantial. 
Besides the sample size allocation restriction, another limitation of method 1 is that 
it cannot handle the uncertainties from the experimental treatment effect. An 
underlying assumption for the method 1 to work properly is that the treatment 
effect equals the active comparator effect. In the pragmatic scenarios where there is 
deviation from the assumption, one needs re-evaluate its appropriateness. For 
instance, when ΔAP,Assumed is accurate at the design stage, ΔTP preserves 95% of ΔAP, 
and the non-inferiority threshold is 70% (i.e., 𝜆 = 0.3), with a nominal power of 
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80%, using method 1 the probability of rejecting the null hypotheses at the final 
stage is 64%, no change compared to fixed sample design. It is not surprising 
considering that the sample size recalculation of method 1 is entirely dependent on 
the estimate of ΔAP using the interim data. In contrast, method 2 recalculates the 
sample size to make up the power loss caused by the over-estimation of the 
preserved fraction of the treatment effect. In a certain scenario, where the 
experimental treatment effect is better than the active comparator, and the active 
comparator is under-estimated, method 1 provides an actual power even lower than 
the fixed sample design. This is because it allows for sample size reduction. Such 
scenario is not uncommon in the real clinical trials as the clinical conditions 
improves over time.  One way to avoid such issue in method 1 is to not allow 
reducing sample size and that is probably what regulatory agencies recommend. In 
terms of efficiency method 2 outperforms method 1 in most cases as it often needs 
smaller average sample size. This observation is predictable because in method 2 
there is chance to stop the study for excessive efficacy at the interim stage. 
Table 10 Comparisons of actual power and average sample size (in the parenthesis) 
between method 1 and method 2 
𝚫T𝐏,𝐓𝐫𝐮𝐞/𝚫𝐀𝐏,𝐓𝐫𝐮𝐞 𝚫A𝐏,𝐓𝐫𝐮𝐞/𝚫𝐀𝐏,Assumed 
Actual Power (Average Sample Size) 
No SSR Method I Method II 
1 1/√2 51 (383) 78 (854) 57 (445) 
 1 80 (383) 77 (421) 84 (414) 
 1.1 86 (383) 78 (344) 89 (396) 
0.95 1/√2 38 (383) 62 (854) 44 (452) 
 1 65 (383) 64 (421) 71 (438) 
 1.1 73 (383) 64 (344) 78 (428) 
1.1 1/√2 75 (383) 91 (854) 80 (428) 
 1 96 (383) 93 (421) 97 (346) 
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 1.1 98 (383) 93 (344) 99 (315) 
 
Note: 𝝀 = 𝟎. 𝟑,  𝚫𝐀𝐏,𝐀𝐬𝐬𝐮𝐦𝐞𝐝 = 𝚫𝐓𝐏,𝐀𝐬𝐬𝐮𝐦𝐞𝐝 = 𝟎.𝟔𝟎, nominal 𝜶=2.5%, nominal power = 80%, number of 
simulations=100,000. 
 
 
3.2 Effect Preservation Test, Binary Endpoint 
In many clinical trials the primary endpoint can be the risk of a certain event, such 
as mortality, stroke and etc. In such studies the primary outcome is collected as a 
binary variable. The underlying distribution for such endpoint X𝑖 is Binominal 
(N𝑖, π𝑖), 𝑖 = 𝑇, 𝐴, 𝑃, where X𝑖 is the number of success in the ith arm, N𝑖 is the number 
of subjects in the ith arm, and π𝑖 is the success rate of each arm. The testing 
procedures designed for normal endpoints may no longer be appropriate. The most 
common parametric model for binary outcome is assuming binomial distributions, 
in which the variance is linked to the mean, as a result, the optimal allocation will no 
longer take the simple form as in cases with normal endpoint. Another challenge is 
that there is no analytical solution for the variance estimate of the test statistic. The 
restricted maximum likelihood estimate has to be calculated using the Newton-
Raphson algorithm. These challenges will be discussed in detail in this section, and 
the performance of the conditional power-based sample size recalculation for such 
studies will be investigated through Monte Carlo simulations.  
3.2.1 Hypothesis, Test Statistics and Sample Size 
Let π𝑇, π𝐴, π𝑃 denote the success rate of the binary outcome of treatment, active 
comparator and placebo respectively.  
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The hypotheses testing procedure will include  
𝐻0,𝐴𝑃
(𝑠)
: π𝐴 ≤ π𝑃 versus 𝐻1,𝐴𝑃
(𝑠)
: π𝐴 > π𝑃    
𝐻0,𝑇𝐴
(𝑛)
: 
π𝑇−π𝑃
π𝐴−π𝑃
≤ 1 − 𝜆  versus 𝐻1,𝑇𝐴
(𝑛)
: 
π𝑇−π𝑃
π𝐴−π𝑃
> 1 − 𝜆  
Again, due to the natural hierarchy, the fixed sequence testing procedure is the most 
appropriate approach for the type I error control.  
The construction and estimation of test statistics for the binary outcome is similar 
but more complicated than normally distributed outcome.  
Let θ = π𝑇 − (1 − 𝜆)π𝐴 − 𝜆π𝑝 , the estimate θ̂ = 𝑃𝑇 − (1 − 𝜆)𝑃𝐴 − 𝜆𝑃𝑃, where 𝑃𝑖 =
X𝑖
N𝑖
, i=T, A, P 
The variance of θ̂ 
𝑉𝑎𝑟(θ̂) = {π𝑇(1 − π𝑇) +
(1−λ)2π𝐴(1−π𝐴)
cA
+
λ2π𝑃(1−π𝑃)
cP
}
1
n𝑇
   
can have various estimates depending on the estimated (π𝑇, π𝐴, π𝑃 ) to be plugged in. 
Plugging in the maximum likelihood estimates (𝑃𝑇, 𝑃𝐴, 𝑃𝑃 ) yields Wald’s statistic. 
We could also substitute π𝑖′𝑠 by the restricted maximum likelihood estimate 
(RMLE), for which the estimates are made under null hypothesis, i.e., ?̂?𝑇 − (1 −
𝜆)?̂?𝐴 − 𝜆?̂?𝑝 = 0. The RMLE is identical to the score statistic and is equivalent to the 
test proposed by Miettinen and Nurminen27 and Farrington and Manning28 for two-
arm non-inferiority trials. In Kieser and Friede’s work (2007)29 it is found that the 
RMLE based test statistic is more conservative and is much better at controlling the 
type I error compared to the Wald-type test statistics.  
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Sample size for the non-inferiority test 
Let 𝜏0
2, 𝜏1
2 denote n𝑇𝑉𝑎𝑟(θ̂) under null and alternative hypothesis respectively, the 
power function for the non-inferiority test can then be derived as  
1 − 𝛽 = 𝑃 (√
nTθ̂
𝜏0 
> z1−α|H1) = 1 − Φ(
z1−α𝜏0
𝜏1
−
√nTθ1
𝜏1 
) 
The sample size for the non-inferiority test is calculated as  
𝑁01 = nT(1 + cA + cP) =
(z1−α𝜏0 + z1−β𝜏1)
2
(1 + cA + cP)
𝜃1
2  
It may be simplified by substituting 𝜏0 with 𝜏1 or vise verse to either  
𝑁00 =
(𝑧1−𝛼 + 𝑧1−𝛽)
2
𝜏0
2(1 + 𝑐𝐴 + 𝑐𝑃)
𝜃1
2  
or 
𝑁11 =
(z1−α + z1−β)
2
𝜏1
2(1 + cA + cP)
𝜃1
2  
Simulations were conducted to compare the accuracy and efficiency of the three 
formula of sample size calculations. We considered a nominal level α=2.5%, desired 
power=80%, balanced allocation at various combinations of preservation margin 
(𝜆) and success rates (π𝑇 , π𝐴, π𝑝) .   Table 10 shows the calculated sample sizes and 
the actual power from simulations. 
Table 11 Comparisons of sample sizes and actual power based on different variance 
values for the test statistics of the preservation non-inferiority test on binary 
endpoint 
    𝑁01  𝑁00  𝑁11  
λ π𝑇 π𝐴 π𝑝 Sample 
size 
Actual 
power 
Sample 
size 
Actual 
power 
Sample 
size 
Actual 
power 
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0.1 0.9 0.9 0.1 750 0.854 816 0.883 603 0.768 
0.1 0.9 0.9 0.3 1281 0.827 1371 0.855 1080 0.747 
0.1 0.6 0.6 0.1 4152 0.807 4173 0.811 4101 0.796 
0.3 0.9 0.9 0.1 96 0.839 114 0.903 60 0.564 
0.3 0.9 0.9 0.3 168 0.858 195 0.906 114 0.661 
0.3 0.6 0.6 0.3 1116 0.795 1125 0.806 1095 0.790 
0.5 0.9 0.9 0.1 36 0.779 45 0.878 21 0.467 
0.5 0.8 0.9 0.1 72 0.796 78 0.841 54 0.667 
0.5 0.7 0.6 0.1 60 0.782 60 0.782 57 0.764 
Note: Nominal 𝛼=2.5%, nominal power=80%, number of simulations=10,000. 
 
It can be seen that for all considered parameter combinations the sample size 𝑁01 
gives the power closest to the nominal power. The 𝑁00 always gives a power bigger 
than the desired power and is sometimes not as efficient. It can go 20% above the 
needed sample size.  𝑁11 showed bad performance when the sample size is small. In 
certain investigated cases the power for 𝑁11 went as low as 47%. This finding agrees 
with the calculations done by Kieser and Friede29.  
Sample size for the entire test procedure 
In chapter 1.4.2 it is proved that for normally distributed endpoint with common 
variance, at λ ≤ 0.5, the sample size required for the non-inferiority test is always 
larger than the sensitivity test. For the binary endpoint due to the link between 
mean and variance we need re-visit the sample size comparison between the two 
tests to see if this conclusion is still true. Assuming an equal success rate of 
experimental treatment and active comparator, the sample size needed for the non-
inferiority test and for the assay sensitivity test are respectively 
nT
NIF =
{(1 +
(1 − λ)2
cA
)π𝐴(1 − π𝐴) +
λ2π𝑃(1 − π𝑃)
cP
} (z1−α + z1−β)
2
λ2ΔAP
2  
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nT
AP =
{
π𝐴(1 − π𝐴)
cA
+
π𝑃(1 − π𝑃)
cP
} (z1−α + z1−β)
2
ΔAP
2
 
By taking the ratio between the nT
NIF and nT
AP: 
𝑟 =
{(1 +
(1 − λ)2
cA
)π𝐴(1 − π𝐴) +
λ2π𝑃(1 − π𝑃)
cP
}
λ2 {
π𝐴(1 − π𝐴)
cA
+
π𝑃(1 − π𝑃)
cP
}
 
=
(
cA − 2λ + 1
cA
)π𝐴(1 − π𝐴) + λ2 {
π𝐴(1 − π𝐴)
cA
+
π𝑃(1 − π𝑃)
cP
}
λ2 {
π𝐴(1 − π𝐴)
cA
+
π𝑃(1 − π𝑃)
cP
}
 
=
(
1 − 2λ + cA
cA
)π𝐴(1 − π𝐴)
λ2 {
π𝐴(1 − π𝐴)
cA
+
π𝑃(1 − π𝑃)
cP
}
+ 1 
 
By observing the above formula, whether r can go below 1 depends on the sign of 
1 − 2λ + cA. Again we are only interested in the scenario with λ ≤ 0.5, in which the 
first term in the above is positive, therefore the ratio is always greater than 1, 
suggesting that the sample size required to achieve a certain power is dominated by 
the non-inferiority test. 
 
 
3.2.2 SSR Methods for Binary outcome 
Let p𝑇, p𝐴, p𝑃 be the observed proportion (success rate) of the experimental 
treatment, active comparator and placebo group π𝑇,𝑖, π𝐴,𝑖, π𝑃,𝑖 be the success rate at 
the null hypothesis (i=0) or alternative hypothesis (i=1); θ̂
(𝑘)
= p
𝑇
(k) − (1 − 𝜆)p
𝐴
(k) −
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𝜆p
𝑃
(k) (k=1, 2-1, 2) . The superscript (1), (2-1)  and (2) respectively indicate the data at 
the interim stage, post interim and throughout the trial. 
The method 1 uses the 𝑁01 for the initial sample size calculation and replace 𝜃1 =
𝜆(π𝐴,1 − π𝑃,1) with 𝜆(p𝐴
(1) − p𝑃
(1)) for the sample size recalculation. The test 
procedure stays the same as for the continuous outcome. 
3.2.2.1 Conditional Power Derivation for Binary Outcome  
The method 2 still depends on the conditional power. The conditional power for the 
non-inferiority test can be derived as follows.  
The test statistic for the interim non-inferiority test is denoted as  
 z1
𝑁𝐼𝐹 =
θ̂(1)
√
?̂?(1)
2
𝑛𝑇
(1)
 
 , then we have  
𝐶𝑃(𝑁𝐼𝐹) = 𝑃
(
 
 
 
θ̂(2)
√
𝜏02
𝑛𝑇
(2)
 
> 𝑐2|𝑍1 = z1
𝑁𝐼𝐹  
)
 
 
 
=  𝑃 (
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
θ̂
(1)
+ (1 −
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
) θ̂
(2−1)
> 𝑐2√
𝜏02
𝑛𝑇
(2)
 
| 𝑍1 = z1
𝑁𝐼𝐹) 
       =  𝑃 (
𝑛𝑇
(1)
 
𝑛𝑇
(2)
 
z1
𝑁𝐼𝐹√
?̂?(1)
2
𝑛𝑇
(1)
 
+
𝑛𝑇
(2)
− 𝑛𝑇
(1)
 
𝑛𝑇
(2)
(θ̂(2−1)) > 𝑐2√
𝜏02
𝑛𝑇
(2)
 
| 𝑍1 = z1
𝑁𝐼𝐹) 
       =  𝑃
(
 θ̂(2−1) >
𝑐2𝜏0√𝑛𝑇
(2) − z1
𝑁𝐼𝐹?̂?(1)√𝑛𝑇
(1)
𝑛𝑇
(2) − 𝑛𝑇
(1)
| 𝑍1 = z1
𝑁𝐼𝐹 , 𝐻1
)
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=  𝑃
(
 
θ̂(2−1) − 𝜃
?̂?(1)/√𝑛𝑇
(2) − 𝑛𝑇
(1)
>
𝑐2𝜏0√𝑛𝑇
(2) − z1
𝑁𝐼𝐹?̂?(1)√𝑛𝑇
(1)
?̂?(1)√𝑛𝑇
(2) − 𝑛𝑇
(1)
−
𝜃
?̂?(1)/√𝑛𝑇
(2) − 𝑛𝑇
(1)
)
  
= 1 − Φ
(
 
𝑐2𝜏0√𝑛𝑇
(2)
 − z1
𝑁𝐼𝐹?̂?(1)√𝑛𝑇
(1)
?̂?(1)√𝑛𝑇
(2)
− 𝑛𝑇
(1)
 −
𝜃√𝑛𝑇
(2) − 𝑛𝑇
(1)
?̂?(1)
)
  
 3.2.2.2 Testing Procedure and Operational Characteristics by Monte-Carlo Simulations 
The performance of the SSR methods for binary outcome is investigated via Monte-
Carlo simulations in this chapter. The familywise type-I error, actual power 
property and efficiency compared to non-adaptive design are examined at various 
parameter combinations.  
Given the nominal type-I error of 2.5%, study power of 80%, we consider several 
combinations of 𝜆 and allocations. For each scenario simulations with 100,000 
replicates were performed. The simulated type-I error and power are the 
proportion of the simulations that cross the boundaries at the final stage. 
Type-I error control 
Due to the nature of the testing procedure, the family-wise type I error of the entire 
procedure is dominated by the non-inferiority test. The investigated scenarios 
include the combination of λ=0.05, 0.2, 0.35, 0.5 and commonly used allocations of 
nT: nA: nP=1:1:1, 2:2:1, 2:1:1, 4:1:1, 1: (1- λ): λ. It is observed from the figure 4 that 
most of the time the type I error is well preserved for method 2. For method 1, the 
type I error inflation is observed more frequently and to a larger extent, up to 5%, 
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even at the sample size allocations with good type I error control for continuous 
outcomes. It could be due to the non-independence between the mean and variance 
for the binary outcomes changes the relationship between the final test statistic and 
the interim ?̂?𝑨𝑷
(𝟏)
.   
Figure 4 Simulation results on the type-I error rates (%) for method 1 and method 2 
for binary outcomes 
 
 
 
Note: The investigated scenarios include the combination of λ=0.05, 0.2, 0.35, 0.5, and nT: nA: 
nP=1:1:1, 2:2:1, 2:1:1, 4:1:1, 1: (1- λ): λ 
 
 
Power and Efficiency 
Simulations were also performed to investigate how the actual power and average 
sample size for the SSR methods, and how it was compared against fixed sample 
design while the true success rates deviate from the assumed values. Table 12 listed 
four representative scenarios. While the true success rates were the same as 
assumed rate, the method 1 yields almost identical power and average sample size 
to that of the fixed sample design. Method 2 yields slightly higher probability of final 
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null hypotheses rejections than the nominal power, with the price of 5% increase of 
average sample size. The chance of recalculating the sample size is 23%. In the 
second scenario the actual preserved effect is still 100% but both experimental 
treatment and active comparator success rates are overestimated by 5% at the 
design stage. In such case, the actual power for the fixed sample size design is 63%. 
The method 1 improve the actual power substantially to 77%. Method 2 design 
increased the actual power to 70%. There is 31% of chance the conditional power 
would fall into the unfavorable zone. The rejection probability in the promising or 
favorable zone are respectively 86% and 89%. In the third hypothetical scenario, 
the success rate in the experimental treatment is overestimated by 1% in the design 
stage, causing 6% of loss of actual power. The actual power using method 1 design 
equals the nominal power. It is because the active comparator success rate is 
accurate and there is very likely the sample size is not adapted. Method 2 increases 
the average rejection probability to 71%. The last scenario investigates the 
statistical properties when the assumption of experimental treatment success rate 
is accurate but the assay sensitivity is overestimated. In such case, the actual 
preserved fraction is greater than 100%.  The method 1 design yields an over-
powered study with efficiency even lower than the fixed sample design. In contrast 
the method 2 design has a 64% chance to stop the study for excessive efficacy, 
therefore saves the average sample size by 28%.     
 
Table 12 Simulation results for rejection probability at each conditional power zone 
for the method 2 applied on binary endpoint 
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True values No SSR Method 1 Method 2 
π𝑇  π𝐴  𝜀 
Actual  
Power 
x 100% 
(N) 
Actual  
Power x 
100% 
(N) 
Actual  
Power x 
100% 
(N) 
Interim 
rej. 
prob. 
CP Zone 
Prob. 
Falls into 
each Zone 
Rej. Prob. 
Within each 
Zone 
0.6 0.6 1 80 
(2670) 
79  
(2765) 
84 
(2814) 
16.1% Unfav. 20% 43% 
    
Promising 23% 92% 
    
Fav. 57% 95% 
0.55 0.55 1 64 
(2670) 
77  
(4044) 
70  
(3042) 
9% Unfav. 31% 28% 
 
Promising 27% 86% 
 
Fav. 42% 89% 
0.59 0.6 0.97 65 
(2670) 
64  
(2765) 
71 
(3036) 
10% Unfav. 30% 28% 
 
Promising 26% 87% 
 
Fav. 44% 89% 
0.6 0.55 1.2 96 
(2670) 
99  
(4047)  
99 
(1908) 
64% Unfav. 2% 88% 
 
Promising 5% >99% 
 
Fav. 93% >99% 
Note: The numbers in parenthesis are the actual power without sample size recalculation; nominal 𝛼=2.5%,  1-
λ=0.8, Alternative hypothesis: π𝑃,𝑎=0.3, π𝐴,𝑎=0.6, π𝑇,𝑎 = 0.6; Nominal 𝛼 =0.025 (one-sided), nominal power for 
Non-inferiority test = 80%, 𝜀 =
πT- πp
πA- πp
, balanced allocation, number of simulations=50,000. 
 
 
 
3.3 Conclusion and Discussion 
There are quite a few factors to be considered when designing three-arm non-
inferiority trial. According to the findings in this thesis, if there is limited prior 
information to generate a clinically relevant margin, the effect preservation test is 
preferred over the fixed margin test because of higher efficiency to claim study 
success when the margin of 𝜆Δ𝐴𝑃 is numerically identical to the fixed margin. The 
adaptive design with sample size recalculation is advocated for such trial because of 
the great uncertainties on many aspects, such as the experimental treatment 
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efficacy, the assay sensitivity and the margin. The sample size recalculation method 
1 proposed by Schwartz and Denne does not require unblinding the treatment 
efficacy result and is likely to be a practical choice whenever applicable because of 
its straightforward design and interpretation. In this thesis its application was 
extended to a broader range of sample size allocations than the originally proposed 
optimal allocation only. Nevertheless, its usage is still limited to two-stage design 
under certain sample size allocations which does not lead to type I error inflation. In 
addition, it is not under the group sequential design framework and thus does not 
allow for the study to stop in the interim stage for over-efficacy or futility. The 
method 2 introduced to the three-arm non-inferiority setting in this thesis 
calculates the conditional power for the non-inferiority test at the interim stage. If 
the conditional power falls into the promising zone the sample size may be re-
calculated and the final test can proceed without adjustment. When the assay 
sensitivity was under-estimated at the design stage or when the assumed 
experimental treatment effect deviates from the true value, this conditional power 
approach could either increase the trial efficiency by allowing the study to stop 
early. The stop criteria would have to be specified at the planning stage and be 
agreed upon by the study clinician and regulatory reviewer. We also looked into the 
statistical properties of this method in studies with binary outcomes. The restricted 
maximum likelihood estimate was used to construct the test statistics. Based on the 
simulations, it is found that the type I error was preserved in the investigated 
scenarios. The overall study power increases by 4 to 7% compared to the fixed 
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sample design. When the efficacy was under-estimated at the design stage, the 
average sample size can reduce dramatically compared to fixed sample design due 
to the chances of rejection at the interim stage.  
In this work we have assumed the continuous outcomes follow normal distributions 
with known common variance. In practice the sample variance could be used for the 
sample size and conditional power calculations. This will introduce deviation from 
normality and additional variability. Further investigations may be conducted to 
evaluate the impact of this.  In real studies it is often not recommended to reduce 
the sample size for an over-powered study. Therefore when applying the method 1 
in real studies the efficiency may be lower than what we see in this thesis. The 
limitation of method 2 is the low chance of having the interim results in the 
promising zone at overly optimistic assumptions, in which case the sample size re-
estimation is not triggered at all. One way to get around this may be a combination 
of method 1 and method 2, i.e., use the sample size allocations that will not inflate 
type I error for method 1, do the sample size adaptation if the conditional power 
falls into promising zone as well as below the promising zone but not unacceptably 
low.   
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APPENDIX I Overall Power for Three Tests 
𝑇𝐴𝑃
(𝑠)
, 𝑇𝑇𝑃
(𝑠)
, 𝑇𝑇𝐴
(𝑛)
 follows Multivariate Normal distribution. Assume the design is to test 
𝐻0,𝐴𝑃
(𝑠)
 and 𝐻0,𝑇𝑃
(𝑠)
 both at a significance level of 𝛼/2, and proceed to the test of  𝐻0,𝑇𝐴
(𝑛)
 at 
a significance level of 𝛼 only when both superiority tests against placebo are 
successful. This way the overall type I error is well controlled at 𝛼. Under the 
alternative hypothesis of 𝜇𝑇 = 𝜇𝐴, the overall power function can be derived as  
1 − 𝛽 = 𝛷𝜮(
𝜇𝐴−𝜇𝑃
𝜎
√𝑛𝑇
√
1
𝑐𝐴
+
1
𝑐𝑃
− 𝑧1−𝛼/2,  
𝜇𝑇−𝜇𝑃
𝜎
√𝑛𝑇
√1+
1
𝑐𝑃
− 𝑧1−𝛼/2,
𝜆(𝜇𝐴−𝜇𝑃)
𝜎
√𝑛𝑇
√1+
(1−𝜆)2
𝑐𝐴
+
𝜆2
𝑐𝑃
− 𝑧1−𝛼)           
  
Where 𝜮 =
[
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𝑐𝑃
)
𝟏
]
 
 
 
 
 
 
 
 
 
 
,  Φ𝚺 is the 
CDF of bivariate normal distribution with mean 0 and covariance 𝚺.  
Assuming the 𝜇𝑇 = 𝜇𝐴 = 2, 𝜇𝑃 = 0.5, 𝜎 = 1, 𝛼 = 0.05, 𝜆 = 0.3, the plot of power 
functions (below) suggest that the overall power is determined by the non-
inferiority test. Such trend is representative for all the pragmatic parameter 
combinations explored. Tuning the parameters with the 𝜆 capped at 0.5, the point 
where the overall power curve and noninferiority test power curve converge may 
vary but always locates before the nominal power.  
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APPENDIX II R code for the simulations 
Method 1, continuous outcome 
 
##Input Parameters:  
#alpha nominal significance level 
#beta   nominal type II error (i.e., 1 – power) 
# F  information fraction, i.e., the fraction of sample size at the interim stage 
#muT, muA and muP true efficacy mean of the experimental treatment arm, active 
comparator arm and placebo arm respectively 
#deltaAP.d assumed efficacy difference between active comparator and placebo 
#sigma  common standard deviation of the three arms 
#lambda fraction margin of the effect preservation test 
#cA     the ratio of sample size in the active comparator arm over the experimental 
treatment arm 
#cP      the ratio of sample size in the placebo arm over the experimental treatment arm 
#Nsimu number of simulations 
 
##Output 
#pctRej percentage calculated as the number of rejections at the final stage among all the 
total number of simulated trials, i.e., the actual power by simulation 
#avg_nT.r average number of recalculated sample size of the experimental treatment arm 
 
Method1 <- function(alpha=0.025, beta=0.2, F, detAP.d, muT, muA, muP, sigma, lambda, cA, 
cP, Nsimu) { 
  Za <- qnorm(1-alpha) 
  Zb <- qnorm(1-beta) 
# Initial sample size based on the deltaAP at the design stage # 
  nT <- ceiling((Za+Zb)^2*sigma^2*(1+(1-lambda)^2/cA+lambda^2/cP)/ 
(lambda^2*detAP.d^2)) 
  nA <- ceiling(cA*nT) 
  nP <- ceiling(cP*nT) 
   
  nT.1 <- ceiling(nT*F) 
  nA.1 <- ceiling(nA*F) 
  nP.1 <- ceiling(nP*F) 
   
  set.seed(123456) 
  AllRej=0 
  AllnT.r=NULL 
  for (N in 1:Nsimu)  
  { 
    XT1 <- rnorm(n=nT.1, mean=muT, sd=sigma) 
    XA1 <- rnorm(n=nA.1, mean=muA, sd=sigma) 
    XP1 <- rnorm(n=nP.1, mean=muP, sd=sigma) 
     
    detAP.1=mean(XA1)-mean(XP1); 
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    nT.r <- ceiling((Za+Zb)^2*sigma^2*(1+(1-lambda)^2/cA+lambda^2/cP)/ 
(lambda^2*detAP.1^2)) 
    nT.r=min(4*nT, nT.r) 
    if (nT.r<=nT.1) (nT.r=nT.1+1) 
    nA.r <- ceiling(cA*nT.r) 
    nP.r <- ceiling(cP*nT.r) 
   
     
    XT2 <- rnorm(n=nT.r-nT.1, mean=muT, sd=sigma) 
    XA2 <- rnorm(n=nA.r-nA.1, mean=muA, sd=sigma) 
    XP2 <- rnorm(n=nP.r-nP.1, mean=muP, sd=sigma) 
     
    XTbar=mean(c(XT1, XT2)) 
    XAbar=mean(c(XA1, XA2)) 
    XPbar=mean(c(XP1, XP2)) 
     
    z.AP.f=(XAbar-XPbar)/sigma/sqrt(1/nA.r+1/nP.r) 
    Rej.AP=z.AP.f>Za 
     
    Z.TA.f=(XTbar-(1-lambda)*XAbar-lambda*XPbar)/sigma/sqrt(1/nT.r+(1-
lambda)^2/nA.r+lambda^2/nP.r) 
    Rej.TA=(Z.AF.f>Za) 
    Rej=min(Rej.AP, Rej.TA) 
     
    AllRej=AllRej+min(Rej.AP, Rej.TA) 
    AllnT.r=cbind(AllnT.r, nT.r) 
  } 
  pctRej=AllRej/Nsimu 
  avg_nT.r=mean(AllnT.r) 
  return(list(pctRej, avg_nT.r)) 
} 
 
#Example 1: Simulate overall Type I error for λ=0.5 and µT= µP + λ(µA - µP)  
Method1(detAP.d=1.5 F=0.5,, muT=1.25, muA=2, muP=0.5, sigma=1, lambda=0.5, cA=1, 
cP=1, , Nsimu=100000)  
 
#Example 2: Simulate actual power for λ=0.1 and µT= µA  
Method1(detAP.d=1.5, F=0.5, muT=2, muA=2, muP=0.5, sigma=1, lambda=0.1, cA=1, cP=1, , 
Nsimu=100000)  
 
Method 2, continuous outcome 
##Input Parameters:  
#alpha nominal significance level 
#beta   nominal type II error (i.e., 1 – power) 
# F  information fraction, i.e., the fraction of sample size at the interim stage 
# CP.u upper bound of the promising zone of the conditional power 
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# CP.l lower bound of the promising zone of the conditional power 
#muT, muA and muP true efficacy mean of the experimental treatment arm, active 
comparator arm and placebo arm respectively 
#deltaAP.d assumed efficacy difference between active comparator and placebo 
#sigma  common standard deviation of the three arms 
#lambda fraction margin of the effect preservation test 
#cA     the ratio of sample size in the active comparator arm over the experimental 
treatment arm 
#cP      the ratio of sample size in the placebo arm over the experimental treatment arm 
#Nsimu number of simulations 
 
##Output 
#pctRej percentage calculated as the number of rejections at the final stage among all the 
total number of simulated trials, i.e., the actual power by simulation 
#avgss average number of recalculated sample size of the experimental treatment arm 
#intrej the probability of rejection at the interim stage for excessive efficacy 
#unfzone a list with two elements; the first element is the probability of falling into the 
unfavorable zone and the second element is the probability of rejection at the final stage in 
the unfavorable zone 
#pprzone a list with two elements; the first element is the probability of falling into the 
promising zone and the second element is the probability of rejection at the final stage in 
the promising zone 
#pfavzone a list with two elements; the first element is the probability of falling into the 
favorable zone and the second element is the probability of rejection at the final stage in the 
favorable zone 
 
Method2 <- function(alpha, beta, F, CP.u, CP.l, detAP.d, muT, muA, muP, sigma, lambda, cA, 
cP, Nsimu) { 
library(ldbounds) 
Za <- qnorm(1-alpha) 
Zb <- qnorm(1-beta) 
obf.bd=bounds(t=c(0.5,1), iuse=1, alpha=alpha) 
c1tilda=obf.bd$upper.bounds[1] 
c2tilda=obf.bd$upper.bounds[2] 
 
M=1+(1-lambda)^2/cA+lambda^2/cP 
 
nT <- ceiling((c2tilda+Zb)^2*sigma^2*M/(lambda^2*detAP.d^2)) 
nA <- ceiling(cA*nT) 
nP <- ceiling(cP*nT) 
 
 
nT.1 <- ceiling(nT*F) 
nA.1 <- ceiling(nA*F) 
nP.1 <- ceiling(nP*F) 
 
set.seed(123456) 
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AllRej=0 
interim=0 
zone=NULL 
AllnT.r=NULL 
 
for (N in 1:Nsimu) 
{ 
XT1 <- rnorm(n=nT.1, mean=muT, sd=sigma) 
XA1 <- rnorm(n=nA.1, mean=muA, sd=sigma) 
XP1 <- rnorm(n=nP.1, mean=muP, sd=sigma) 
 
detAP.1=mean(XA1)-mean(XP1); 
z.AP.1=detAP.1/sigma/sqrt(1/nA.1+1/nP.1) 
Rej.AP1=z.AP.1>c1tilda 
 
theta1=mean(XT1)-(1-lambda)*mean(XA1)-lambda*mean(XP1) 
Z.1=theta1/sigma/sqrt(M/nT.1) 
Rej.TA1=Z.1>c1tilda 
 
Rej1=min(Rej.AP1, Rej.TA1) 
 
if (Rej1==1) { 
nT.r=nT.1 
AllRej=AllRej+Rej1 
rejseq=cbind(rejseq, Rej1) 
AllnT.r=cbind(AllnT.r, nT.1) 
interim=interim+1 
zone=cbind(zone, 1) 
 
} else { 
 
#Conditional power 
CP=1-pnorm((c2tilda*sqrt(nT)-Z.1*sqrt(nT.1))/sqrt(nT-nT.1)-theta1/sigma/sqrt(M/(nT-
nT.1))) 
if (CP<CP.l) {zone=cbind(zone, -1)}  
if (CP>CP.u) {zone=cbind(zone, 1)} 
if (CP>=CP.l & CP<=CP.u) { 
zone=cbind(zone, 0) 
CP0=CP 
nT.r=nT 
while(CP0<1-beta && nT.r<=4*nT){ 
  nT.r=nT.r+1 
  CP0=1-pnorm((c2tilda*sqrt(nT.r)-Z.1*sqrt(nT.1))/sqrt(nT.r-nT.1)-
theta1/sigma/sqrt(M/(nT.r-nT.1))) 
  } 
} else { 
#if not in promising zone, continue w/o changing sample size 
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nT.r <- nT 
} 
 
nA.r <- ceiling(cA*nT.r) 
nP.r <- ceiling(cP*nT.r) 
 
XT2 <- rnorm(n=nT.r-nT.1, mean=muT, sd=sigma) 
XA2 <- rnorm(n=nA.r-nA.1, mean=muA, sd=sigma) 
XP2 <- rnorm(n=nP.r-nP.1, mean=muP, sd=sigma) 
 
XTbar=mean(c(XT1, XT2)) 
XAbar=mean(c(XA1, XA2)) 
XPbar=mean(c(XP1, XP2)) 
 
if (Rej.AP1==1) { Rej.AP=1 } else { 
z.AP.f=(XAbar-XPbar)/sigma/sqrt(1/nA.r+1/nP.r) 
Rej.AP=z.AP.f>c2tilda } 
 
Z.f=(XTbar-(1-lambda)*XAbar-lambda*XPbar)/sigma/sqrt(1/nT.r+(1-
lambda)^2/nA.r+lambda^2/nP.r) 
Rej=Z.f>c2tilda 
 
AllRej=AllRej+min(Rej.AP, Rej) 
rejseq=cbind(rejseq, min(Rej.AP, Rej)) 
AllnT.r=cbind(AllnT.r, nT.r) 
} 
} # end of for loop 
pctRej=AllRej/Nsimu 
avg_nT.r=mean(AllnT.r) 
nT.r_nT=avg_nT.r/nT 
unf=sum(zone==-1) 
prom=sum(zone==0) 
fav=sum(zone==1) 
punf=sum(rejseq[which(zone==-1)])/unf 
ppr=sum(rejseq[which(zone==0)])/prom 
pfav=sum(rejseq[which(zone==1)])/fav 
 
result <- list(power=pctRej, avgss=avg_nT.r, intrej=interim/Nsimu, unfzone=c(unf/Nsimu, 
punf), pprzone=c(prom/Nsimu, ppr), pfavzone=c(fav/Nsimu, pfav)) 
return(result) 
}  
 
#Example 1: Simulate overall Type I error for λ=0.5 and µT= µP + λ(µA - µP)  
Method1(detAP.d=1.5, F=0.5, CP.l=0.31, CP.u=0.8, muT=1.25, muA=2, muP=0.5, sigma=1, 
lambda=0.5, cA=1, cP=1, Nsimu=100000)  
 
#Example 2: Simulate actual power for λ=0.1 and µT= µA  
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Method1(detAP.d=1.5, CP.l=0.31, CP.u=0.8, muT=2, muA=2, muP=0.5, sigma=1, lambda=0.1, 
cA=1, cP=1, , Nsimu=100000)  
 
RMLE for the three-arm non-inferiority test with binary outcome 
 
##Input Parameters:  
#XTe, XAe and XPe: The number of success respectively in the experimental treatment arm,  
   active comparator arm and the placebo arm. 
#nTe, nAe, nPe: The available sample size respectively in the experimental treatment arm,  
   active comparator arm and the placebo arm. 
#lambda fraction margin of the effect preservation test 
 
##Output: 
# piT.hat, piA.hat and piP.hat The restricted MLE for each arm found by Newton–Raphson 
algorithm. If the local restriction is not found after 100,000 iterations the unrestricted MLE 
will be given. 
 
RMLE <- function(XTe, XAe, XPe, nTe, nAe, nPe, lambda) { 
 
iA=XAe/nAe 
iP=XPe/nPe 
 
if (iA==1 || iA==0) {iA=runif(1, 0.1, 0.9)} 
if (iP==1 || iP==0) {iP=runif(1, 0.1, 0.9)} 
 
xi=c(iA, iP) 
dd=c(1,1) 
iter=0 
s1=1  
s2=1 
s3=1 
 
while ((dd[1]>1e-8 || dd[2]>1e-8)&&(s1>1e-10 || s2>1e-10 || s3>1e-10)) { 
iter=iter+1 
 
J=matrix(c(1,1,2,2), nrow=2) 
intJ=1 
 while (rankMatrix(J)<2) { 
  intJ+1 
  m11=-XTe*(1-lambda)/((1-lambda)*xi[1]+lambda*xi[2])^2-XAe/xi[1]^2 
  m12=-XTe*lambda/((1-lambda)*xi[1]+lambda*xi[2])^2-XPe/xi[2]^2 
  m21=(nTe-XTe)*(1-lambda)/(1-(1-lambda)*xi[1]-lambda*xi[2])^2+(nAe-XAe)/(1-
xi[1])^2 
  m22=(nTe-XTe)*lambda/(1-(1-lambda)*xi[1]-lambda*xi[2])^2+(nPe-XPe)/(1-xi[2])^2 
  J=matrix(data=c(m11, m21, m12, m22), nrow=2, ncol=2) 
  if (rankMatrix(J)<2) {xi=runif(2, 0.1, 0.9)} 
  } 
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f11=XTe/((1-lambda)*xi[1]+lambda*xi[2])+XAe/xi[1]+XPe/xi[2]-(nTe+nAe+nPe) 
f21=(nTe-XTe)/(1-(1-lambda)*xi[1]-lambda*xi[2])+(nAe-XAe)/(1-xi[1])+(nPe-XPe)/(1-
xi[2])-(nTe+nAe+nPe) 
F=c(f11, f21) 
 
 
 
xii=xi-solve(J)%*%F 
dd=abs(xii-xi)  
xi=xii  
 
if (iter>100000) {break 
  piA.hat=XAe/nAe 
  piT.hat=XTe/nTe 
  piP.hat=XPe/nPe} 
if ( xi[1]<1e-4 || xi[2]<1e-4 || xi[1]>1-1e-4 || xi[2]>1-1e-4) { 
   iter=iter+1  
   xi=runif(2, 0.1, 0.9)  
} 
  
piA.hat=xii[1] 
piP.hat=xii[2] 
piT.hat=(1-lambda)*piA.hat+lambda*piP.hat 
 
totN=nTe+nAe+nPe 
 
s1=abs(XTe/piT.hat+XAe/piA.hat+XPe/piP.hat-totN) 
s2=abs((nTe-XTe)/(1-piT.hat)+(nAe-XAe)/(1-piA.hat)+(nPe-XPe)/(1-piP.hat)-totN) 
s3=abs(piT.hat-(1-lambda)*piA.hat-lambda*piP.hat) 
} 
 
return(list(piT.hat=piT.hat, piA.hat=piA.hat, piP.hat=piP.hat)) 
 
Method 1, binary outcome 
 
##Input Parameters:  
#alpha nominal significance level 
#beta   nominal type II error (i.e., 1 – power) 
# F  information fraction, i.e., the fraction of sample size at the interim stage 
#PiT.t, piA.t, piP.t  true success rate of the experimental treatment arm, active comparator 
arm and placebo arm respectively 
#PiT.a, piA.a, piP.a assumed success rate of the experimental treatment arm, active 
comparator arm and placebo arm respectively at the trial design stage  
#lambda fraction margin of the effect preservation test 
#cA     the ratio of sample size in the active comparator arm over the experimental 
treatment arm 
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#cP      the ratio of sample size in the placebo arm over the experimental treatment arm 
#Nsimu number of simulations 
##Output 
#pctRej percentage calculated as the number of rejections at the final stage among all the 
total number of simulated trials, i.e., the actual power by simulation 
#avg_nT.r average number of recalculated sample size of the experimental treatment arm 
 
 
Method1.bin <- function(piT.a, piA.a, piP.a, piT.t, piA.t, piP.t, F, lambda, cA, cP, 
Nsimu=10000) { 
    library('gsDesign') 
    tao=function (lambda, pT, pA, pP) { 
            sqrt(pT*(1-pT)+(1-lambda)^2*pA*(1-pA)/cA+lambda^2*pP*(1-pP)/cP) 
             } 
     detAP.a=piA.a-piP.a 
 
  tao.0=tao(lambda, pT.0, pA.0, pP.0) 
  tao.1=tao(lambda, piT.a, piA.a, piP.a) 
   
  nT <- ceiling((Za*tao.0+Zb*tao.1)^2/(lambda*detAP.a)^2) 
  nA <- ceiling(cA*nT) 
  nP <- ceiling(cP*nT) 
   
  nT.1 <- ceiling(nT*F) 
  nA.1 <- ceiling(nA*F) 
  nP.1 <- ceiling(nP*F) 
   
  set.seed(123456) 
  AllRej=0 
  AllnT.r=NULL 
  for (N in 1:Nsimu)  
  { 
    XT1 <- rbinom(1, nT.1, piT.t) 
    XA1 <- rbinom(1, nA.1, piA.t) 
    XP1 <- rbinom(1, nP.1, piP.t) 
     
    pThat1=XT1/nT.1 
    pAhat1=XA1/nA.1 
    pPhat1=XP1/nP.1 
    
    detAP.1=pAhat1-pPhat1; 
     
    nT.r <- ceiling((Za*tao.0+Zb*tao.1)^2/(lambda*detAP.1)^2) 
 
    nT.r=min(4*nT, nT.r) 
    if (nT.r<=nT.1) (nT.r=nT.1+1) 
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    nA.r <- ceiling(cA*nT.r) 
    nP.r <- ceiling(cP*nT.r) 
     
     
    XT2 <- rbinom(1, nT.r-nT.1, piT.t) 
    XA2 <- rbinom(1, nA.r-nA.1, piA.t) 
    XP2 <- rbinom(1, nP.r-nP.1, piP.t) 
     
    pT.f=sum(XT1, XT2)/nT.r 
    pA.f=sum(XA1, XA2)/nA.r 
    pP.f=sum(XP1, XP2)/nP.r 
     
    z.AP.f=testBinomial(sum(XA1, XA2), sum(XP1, XP2), nA.r, nP.r, delta0=0, chisq=0, adj=0, 
scale="Difference", tol=.1e-10) 
    Rej.AP=z.AP.f>Za  
   
    MLE.f <- RMLE(sum(XT1, XT2), sum(XA1, XA2), sum(XP1, XP2), nT.r, nA.r, nP.r, lambda) 
    Z.f=(pT.f-(1-lambda)*pA.f-lambda*pP.f)/sqrt(Sgm(MLE.f$piT.hat, MLE.f$piA.hat, 
MLE.f$piP.hat)/nT.r) 
    Rej=Z.f>Za 
     
    AllRej=AllRej+min(Rej.AP, Rej) 
    AllnT.r=cbind(AllnT.r, nT.r) 
  } 
  pctRej=AllRej/Nsimu 
  avg_nT.r=mean(AllnT.r) 
  return(list(pctRej, avg_nT.r)) 
} 
 
#Example 1: Simulate overall Type I error for λ=0.5 and πT= πP + λ(πA - πP)  
Method1.bin(piT.a=0.8, piA.a=0.8, piP.a=0.2, piT.t=0.5, piA.t=0.8, piP.t=0.2, F=0.5, 
lambda=0.5, cA=1, cP=1, Nsimu=100000)  
 
#Example 2: Simulate actual power for λ=0.1 and πT= πA  
Method1.bin(piT.a=0.8, piA.a=0.8, piP.a=0.2, piT.t=0.8, piA.t=0.8, piP.t=0.2, F=0.5, 
lambda=0.5, cA=1, cP=1, Nsimu=100000)  
 
Method 2, binary outcome 
 
##Input Parameters:  
#alpha nominal significance level 
#beta   nominal type II error (i.e., 1 – power) 
#F  information fraction, i.e., the fraction of sample size at the interim stage 
#CP.u upper bound of the promising zone of the conditional power 
#CP.l lower bound of the promising zone of the conditional power 
#PiT.t, piA.t, piP.t  true success rate of the experimental treatment arm, active comparator 
arm and placebo arm respectively 
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#PiT.a, piA.a, piP.a assumed success rate of the experimental treatment arm, active 
comparator arm and placebo arm respectively at the trial design stage  
#lambda fraction margin of the effect preservation test 
#cA     the ratio of sample size in the active comparator arm over the experimental 
treatment arm 
#cP      the ratio of sample size in the placebo arm over the experimental treatment arm 
#Nsimu number of simulations 
##Output 
#pctRej percentage calculated as the number of rejections at the final stage among all the 
total number of simulated trials, i.e., the actual power by simulation 
#avgss average number of recalculated sample size of the experimental treatment arm 
#intrej the probability of rejection at the interim stage for excessive efficacy 
#unfzone a list with two elements; the first element is the probability of falling into the 
unfavorable zone and the second element is the probability of rejection at the final stage in 
the unfavorable zone 
#pprzone a list with two elements; the first element is the probability of falling into the 
promising zone and the second element is the probability of rejection at the final stage in 
the promising zone 
#pfavzone a list with two elements; the first element is the probability of falling into the 
favorable zone and the second element is the probability of rejection at the final stage in the 
favorable zone 
 
Method2.bin <- function(alpha, beta, F, piT.t, piA.t, piP.t, piT.a, piA.a, piP.a, CP.l, CP.u, 
lambda, cA, cP, Nsimu) { 
library(ldbounds) 
Sgm=function(piT, piA, piP) { 
sgm = piT*(1-piT)+piA*(1-piA)*(1-lambda)^2/cA+piP*(1-piP)*lambda^2/cP 
return(sgm) 
} 
 
obf.bd=bounds(t=c(0.5,1), iuse=1, alpha=alpha) 
c1tilda=obf.bd$upper.bounds[1] 
c2tilda=obf.bd$upper.bounds[2] 
 
tao=function (lambda, pT, pA, pP) { 
  sqrt(pT*(1-pT)+(1-lambda)^2*pA*(1-pA)/cA+lambda^2*pP*(1-pP)/cP) 
} 
tao.0=tao(lambda, pT.0, pA.0, pP.0) 
tao.1=tao(lambda, piT.a, piA.a, piP.a) 
phi1=piT.a-(1-lambda)*piA.a-lambda*piP.a 
nT <- ceiling((c2tilda*tao.0+Zb*tao.1)^2/(phi1)^2) 
nA <- ceiling(cA*nT) 
nP <- ceiling(cP*nT) 
 
nT.1 <- ceiling(nT*0.5) 
nA.1 <- ceiling(nA*0.5) 
nP.1 <- ceiling(nP*0.5) 
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set.seed(123456) 
AllRej=0 
interim=0 
zone=NULL 
AllnT.r=NULL 
rejseq=NULL 
 
for (N in 1:Nsimu) 
{ 
XT1 <- rbinom(1, nT.1, piT.t) 
XA1 <- rbinom(1, nA.1, piA.t) 
XP1 <- rbinom(1, nP.1, piP.t) 
 
pThat1=XT1/nT.1 
pAhat1=XA1/nA.1 
pPhat1=XP1/nP.1 
 
 
z.AP.1=testBinomial(XA1, XP1, nA.1, nP.1, delta0=0, chisq=0, adj=0, scale="Difference", 
tol=.1e-10) 
Rej.AP1= (z.AP.1>c1tilda) 
 
RMLE1 <- RMLE(XT1, XA1, XP1, nT.1, nA.1, nP.1, lambda) 
theta1=pThat1-(1-lambda)*pAhat1-lambda*pPhat1 
Z.1=theta1/sqrt(Sgm(RMLE1$piT.hat, RMLE1$piA.hat, RMLE1$piP.hat)/nT.1) 
Rej.TA1=Z.1>c1tilda 
 
Rej1=min(Rej.AP1, Rej.TA1) 
 
if (Rej1==1) { 
nT.r=nT.1 
AllRej=AllRej+Rej1 
rejseq=cbind(rejseq, Rej1) 
AllnT.r=cbind(AllnT.r, nT.1) 
interim=interim+1 
zone=cbind(zone, 1) 
} else { 
 
tao0hat=sqrt(Sgm(RMLE1$piT.hat,RMLE1$piA.hat, RMLE1$piP.hat)) 
CP=1-pnorm((c2tilda*sqrt(nT)-Z.1*sqrt(nT.1))*tao0hat/tao1/sqrt(nT-nT.1)-
theta1/tao1/(nT-nT.1)) 
if (CP<CP.l) {zone=cbind(zone, -1)}  
if (CP>CP.u) {zone=cbind(zone, 1)} 
if (CP>=CP.l & CP<=CP.u) { 
zone=cbind(zone, 0) 
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#nT.r=nT.1+Sgm(MLE$piT.hat, MLE$piA.hat, MLE$piP.hat)/(theta1)^2*((c2tilda*sqrt(nT)-
Z.1*sqrt(nT.1))/sqrt(nT-nT.1)+Zb)^2 
#nT.r=min(nT.r, 4*nT) 
nT.r=nT 
CP.d=CP 
while (CP.d<=1-beta && nT.r < 4*nT ) { 
  nT.r=nT.r+1 
  CP.d=1-pnorm((c2tilda*sqrt(nT.r)-Z.1*sqrt(nT.1))/sqrt(nT.r-nT.1)-
theta1/sqrt(Sgm(MLE$piT.hat, MLE$piA.hat, MLE$piP.hat)/(nT.r-nT.1))) 
}  
 #4*nT as upper limit for sample size increase 
} else { 
#if not in promising zone, continue w/o changing sample size 
nT.r <- nT 
} 
 
nT.r <- ceiling(nT.r) 
nA.r <- ceiling(cA*nT.r) 
nP.r <- ceiling(cP*nT.r) 
 
 
XT2 <- rbinom(1, nT.r-nT.1, piT.t) 
XA2 <- rbinom(1, nA.r-nA.1, piA.t) 
XP2 <- rbinom(1, nP.r-nP.1, piP.t) 
 
pT.f=sum(XT1, XT2)/nT.r 
pA.f=sum(XA1, XA2)/nA.r 
pP.f=sum(XP1, XP2)/nP.r 
 
if (Rej.AP1==1) { Rej.AP=1 } else { 
z.AP.f=testBinomial(sum(XA1, XA2), sum(XP1, XP2), nA.r, nP.r, delta0=0, chisq=0, adj=0, 
scale="Difference", tol=.1e-10) 
Rej.AP=z.AP.f>c2tilda } 
 
RMLE.f <- RMLE(sum(XT1, XT2), sum(XA1, XA2), sum(XP1, XP2), nT.r, nA.r, nP.r, lambda) 
Z.f=(pT.f-(1-lambda)*pA.f-lambda*pP.f)/sqrt(Sgm(RMLE.f$piT.hat, RMLE.f$piA.hat, 
RMLE.f$piP.hat)/nT.r) 
Rej=Z.f>c2tilda 
 
AllRej=AllRej+min(Rej.AP, Rej) 
rejseq=cbind(rejseq, min(Rej.AP, Rej)) 
AllnT.r=cbind(AllnT.r, nT.r) 
} 
} # end of for loop 
pctRej=AllRej/Nsimu 
avg_nT.r=mean(AllnT.r) 
nT.r_nT=avg_nT.r/nT 
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unf=sum(zone==-1) 
prom=sum(zone==0) 
fav=sum(zone==1) 
punf=sum(rejseq[which(zone==-1)])/unf 
ppr=sum(rejseq[which(zone==0)])/prom 
pfav=sum(rejseq[which(zone==1)])/fav 
 
result <- list(power=pctRej, avgss=avg_nT.r, ratio=nT.r_nT, intrej=interim/Nsimu, 
               unfzone=c(unf/Nsimu, punf), pprzone=c(prom/Nsimu, ppr), 
pfavzone=c(fav/Nsimu, pfav)) 
return(result) 
}  
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